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Abstract 
Peripheral inflammation can profoundly alter motivational processes and generate 
behavioral symptoms of sickness. Microglia, the innate immune cells of the brain, 
orchestrate neuroinflammation and have long been thought to be important for sickness 
behavior. However, their precise roles remain obscure due to their complex bidirectional 
interactions with neurons in vivo, which regulate how microglia respond to inflammatory 
signals and interact with neurons. Neuron-microglia interactions can be at least partially 
mediated by various types of G-protein coupled receptors (GPCRs) expressed by 
microglia. Here, we generated a microglia specific hM3Gq-DREADD (designer receptors 
exclusively activated by designer drugs) mouse line in which hM3Gq is selectively 
expressed in microglia, allowing for selective stimulation of calcium signalling in vivo. In 
primary cultures, clozapine-N-oxide (CNO) application induced the predicted rise in 
intracellular Ca
2+
 concentration only in hM3Gq-expressing microglia. In vivo, we 
validated that tamoxifen-induced hM3Gq expression was highly efficient and specific to 
microglia. Systemic administration of CNO (1 mg/kg, i.p.) for 3 consecutive days did not 
cause any changes in behavior indicative of sickness behavior, demonstrating that 
microglial hM3Gq signaling alone did not cause overt inflammatory response in vivo. We 
then challenged these mice with a low-dose lipopolysaccharide (LPS) injection (0.1 
mg/kg i.p.) to trigger bona fide sickness behavior. We found that pre-treatment with CNO 
for 3 days alleviated classic LPS-induced sickness behavior including, depression of 
social interaction and locomotor activity. This treatment also suppressed LPS-induced 
upregulation of mRNA of proinflammatory cytokines in the hippocampus.  Our work 
demonstrates that manipulation of GPCR signalling using this new ‘microglia-DREADD’ 
mouse line can help to reveal how microglia modulates inflammatory responses and 
abnormal behavior in vivo. 
 
Keywords: microglia, neuroinflammation, DREADDs, Lipopolysaccharide, sickness 
behaviour, priming, cytokines, peripheral inflammation  
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Chapter 1 
1. Introduction  
1.1 Background 
Sickness changes the behaviour and physiology of people: it causes a general feeling of 
tiredness, irritability, depressive feelings, and mild cognitive impairment, as well as 
physiological changes characterized by fever, anorexia, and fragmented sleep. Despite a 
widespread notion that they are meaningless side effects of being sick, these symptoms form a 
coordinated physiological adaptation intended to promote recovery of the host (Konsman, 
Parnet, and Dantzer 2002). For instance, anorexia serves as a mechanism for the host to be more 
specific with its diet as certain bacterial pathogens require nutritional iron for their survival 
(Leon-Sicairos et al. 2015). Furthermore, digestion itself is metabolically demanding and 
metabolites produced during fasting are beneficial during bacterial infection (A. Wang et al. 
2016). On the other hand, under sickness the host adjusts behaviours in a way that benefits their 
recovery from infection, for example by rerouting energy reserves (Harrison et al. 2009; Lopes 
2014). While sickness is triggered by exogenous causes such as pathogens (bacteria and virus) 
and tissue damage (injury), proinflammatory cytokines are the endogenous signals produced by 
the immune system responsible for orchestrating sickness behaviour. Proinflammatory cytokines 
signal to the brain, trigger secondary inflammatory responses, and consequently recruit neural 
circuits relevant to sickness behavior (Robert Dantzer and Kelley 2007). A failure to engage in 
sickness behaviours is associated with increased mortality rates (Boltaña et al. 2013; Kluger, 
Ringler, and Anver 1975; Lopes 2014). On the other hand, the immune response, when 
excessive, may contribute to neuropsychiatric disorders and neurodegenerative disease with 
overlapping symptoms with sickness behavior. For instance, accumulating evidence indicate 
aberrant actions of cytokines in the pathophysiology of major depression (R. Dantzer et al. 
1999).  
Microglia, the innate immune cells of the brain, have long been considered as important 
cellular intermediates linking inflammatory response and sickness behavior. These cells are 
activated by peripheral inflammation and centrally produce cytokines and other inflammatory 
molecules (Hanisch and Kettenmann 2007; Nayak, Roth, and McGavern 2014; Ransohoff and 
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Perry 2009; Salter and Beggs 2014), being well positioned to interpret afferent immune signals 
and drive ensuing neuroinflammatory response underlying sickness behaviour.  
Despite a large number of studies in this area, evidence for the contribution of microglia 
to sickness behaviour in vivo is convoluted. This is largely due to the technical difficulty of 
specifically targeting microglia in vivo without affecting other cell types. For example, 
minocycline, an antibiotics that is known to impair microglial function, inevitably affects many 
other cell types, making the interpretation of the data difficult (Garrido-Mesa, Zarzuelo, and 
Gálvez 2013). Here I characterized a new transgenic mouse model that express DREADDs 
(designer receptors exclusively activated by designer drugs), engineered receptors designed to 
respond compounds that in their DREADD-effective doses are inert in other receptors (Nichols 
and Roth 2009)specifically in microglia. By using this mouse line, we manipulated microglial 
function in vivo and examined its consequence in sickness behavior. In order to outline the scope 
of this project, I will first provide a review of research in sickness behaviour, and acknowledge 
mechanisms of peripheral immune signalling to the brain. Next, I will focus on microglia in 
particular, and discuss properties facilitating communication with neurons and their environment, 
particularly GPCRs and calcium signalling. Lastly, I will acknowledge the priming of microglia 
and inflammatory stimuli, and suggest the potential of using chemogenetics (DREADDs) to 
specifically study microglia functioning in vivo.  
1.2. Sickness Behaviour  
1.2.1 Pathogen Detection  
The signaling cascades leading to sickness behaviour initiate when infectious agents in the 
form of bacteria, yeast, or viruses, are detected by peripheral immune cells. These infectious 
agents display pathogen-associated molecular patterns (PAMPs) which are recognized by pattern 
recognition receptors (PRRs) on the immune cells (McCusker and Kelley 2013). The most 
widely studied PRRs are toll-like receptors (TLRs) expressed on the surface of monocytes and 
dendritic cells (McCusker and Kelley 2013). The activation of TLRs by infectious agents triggers 
the synthesis and release of cytokines and other immune molecules. Among various subtypes of 
TLRs, TLR4 is the best characterized. This PRR, in conjunction with the CD14/MD2 complex 
recognizes bacterial endotoxin lipopolysaccharide (LPS), leading to the downstream signaling 
mediated by myeloid differentiation primary response gene 88 (MyD88). This is followed by 
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nuclear factor kappa beta (NF-kB) transduction pathway, resulting in the eventual production of 
proinflammatory cytokines such as IL-1β, TNF-α, and IL-6 (Skelly et al. 2013). These cytokines 
are consequently released into circulation by activated immune cells. LPS, a bacterial endotoxin 
found in the outer membrane of gram-negative bacteria, is a reliable tool used to promote the 
production of proinflammatory cytokines, as well as secretion of  nitric oxide, eicosanoids, and 
reactive oxygen species (ROS) (Qin et al. 2007; Henry et al. 2008; Poon et al. 2015). LPS 
produces many of the types of mediators involved in septic shock (Opal 2010), but sub-septic 
doses are commonly used for investigation of immune-brain signalling. Indeed, the dose 
response effects of LPS have been well characterized (Skelly et al. 2013). 
Importantly, LPS does not infiltrate the blood brain barrier at sub septic doses, nor does it 
compromise blood brain barrier integrity (Banks and Robinson 2010; Banks 2006) This makes it 
a useful tool for investigating the influence of peripheral cytokines on brain mechanisms, since it 
excludes CNS infiltration of circulating monocytes and side effects of a compromised BBB 
integrity. Accordingly, LPS is the most popular tool used to assess sickness behavior in rodent 
models. This can be measured by using various behavioral tests including withdrawal from social 
interactions, inactivity in exploration tasks, anorexia and wasting of body weight, and increased 
time of immobility in forces swim tests (FST) and tail suspension tests (TST) (Konsman, Parnet, 
and Dantzer 2002).  
Since sickness behaviour is a response controlled by the brain, these cytokines must somehow 
signal to the brain. The brain has long been viewed as the “immune privileged organ”. However, 
this view has been changed by a seminal observation made in 1985 when Block and Smith 
discovered immune and nervous system share common ligands and receptors (Blalock, Bost, and 
Smith 1985). The first evidence that proinflammatory cytokines are active in the brain was 
published in 1986 (Besedovsky et al. 1986) when it was shown that administration of IL-1 to 
mice activates the HPA axis, and triggers symptoms of sickness behaviour. It has also been 
shown that the central IL-1 administration decreases the preference to the sweet solution 
saccharin, impairs food stimulus conditioning, and induces social withdrawal (Crestani, Seguy, 
and Dantzer 1991; Kent et al. 1992). Furthermore, cytokine receptors are expressed in the brain, 
for example IL-1R1 (Parnet et al. 1994), and cytokine antagonists injected in the brain block the 
central effects of peripherally administered cytokines (Kent et al. 1992). It is now known that the 
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three classic proinflamamtory cytokines, IL-1β, TNF-α, and IL-6, play necessary roles in 
sickness behaviour. The receptors for these cytokines have been shown to be expressed not only 
in neurons but also in various non-neuronal cells including microglia, astrocytes, brain 
endothelial cells, and perivascular macrophages (S. Rivest 1999). The actions of these cytokines 
induce the synthesis of subsequent cytokines within the same cell, as well as other cell types. In 
other words, the cytokine signals spread and amplify through a positive feedback mechanism 
(Miller et al. 2013). For example, it has been shown that peripheral LPS injection can induce the 
upregulation of IL-1β, IL-6 and TNFα first in microglia, followed by astrocyte (Norden et al. 
2016). Pharmacological tools which decreases cytokine production prevents both sickness and 
depressive-like behavior in mice (O’Connor et al. 2009). Mechanisms which facilitate the 
signalling of these cytokines to the brain will be discussed in the next section.  
1.2.2 Peripheral Immune Signalling to the Brain 
Pathways which facilitate the transmission of cytokine signals to the brain include both 
neural and humoral routes (Figure 1.1). To date, four different mechanisms that are not mutually 
exclusive have been proposed. Here, I will summarize these mechanisms with relevance to 
sickness behaviour.  
1.  Neural Transmission 
Early studies found that immune stimuli are detected by vagal nerve afferents (Figure 1.1, 
top), which then relay electrical signals to the nucleus tractus solitaries (NTS) (Bluthe´, Dantzer, 
and Kelley 1992). Furthermore, LPS administered intraperitoneal caused a rapid induction of 
neuronal activation marker c-Fos, within the NTS (Wan et al. 1993). In line with this, sub 
diaphragmatic vagotomy blocks brain-mediated responses to peripheral injections of LPS or IL-
1β (Fleshner et al. 1998; Simons et al. 1998) (Bluthe et al. 1996b, 1996a). However, in contrast 
with this, vagotomy does not block all symptoms induced by LPS; vagotomy has no effect on 
LPS-induced fever (Hansen et al. 2000; G. N. Luheshi et al. 2000). Furthermore, the vagus nerve 
is likely not the only neural route, since the trigeminal nerve activates neurons within the 
hypothalamus modulating feeding behaviour (Malick et al. 2001), while the glossopharyngeal 
nerve may also play a role (Romeo et al. 2001). Nevertheless, these studies demonstrate that 
neural input to the brain at least partly plays roles in transmitting sickness information from the 
periphery to the brain.  
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2. Circumventricular Organs (CVOs) 
The circumventricular organs are a group of unique structures which lack the blood brain-
barrier, and are thus susceptible to systemic circulation. They include: the subfornical organ 
(SFO), vascular organ of the lamina terminalis (OVLT), pineal gland, subcommissural organ 
(SCO), median eminence/neurohypophysial complex, the area postrema, and the choroid plexus 
(Banks 2006). Macrophage like cells residing in the BBB and circumventricular organs where 
the blood brain barrier is leaky  respond to peripheral inflammatory signals, by producing 
proinflammatory cytokines (Vitkovic et al. 2000). It is believed these locally produced cytokines 
then gain entry to the brain via volume diffusion (Figure 1.1, bottom) (N. Quan, Whiteside, and 
Herkenham 1998). Indeed, at early time points after i.p. injection of LPS, IL-1β mRNA is 
upregulated by cells in the BBB and circumventricular organs (CVOs), while sustained IL-1β 
activity in the CNS is derived from glia (N. Quan, Whiteside, and Herkenham 1998). To date, it 
has been shown that IL-1β, IL-6, TNFα, IL-10, and other cytokines are secreted from the choroid 
plexus and brain endothelial cells (Ning Quan and Banks 2007).  
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Figure 1.1 
 
 
Figure 1.1 Immune-Brain signalling pathways  
The brain and the immune system communicate through different mechanisms. (Top) PAMPs 
and cytokines produced in the periphery stimulate vagal nerve afferents which then relay 
electrical signals to the nucleus tractus solitaries (NTS) and downstream pathways. (Bottom) 
Humoral pathways also involve peripherally produced PAMPs and cytokines, which reach the 
brain at areas where the blood brain barrier is leaky. Including the circumventricular organs and 
choroid plexus (CP). In the circumventricular organs, PAMPS induce the production of 
proinflammatory cytokines, which are believe to gain entry into the brain by volume diffusion or 
other mechanisms.  
Modified from (Robert Dantzer et al. 2008). Copyright Nature Reviews Neuroscience 2007. 
Reprinted with permission.  
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3. Saturable Transport Mechanisms  
While cytokines are large molecules that do not freely cross the BBB, there is evidence for 
saturable transport of cytokines across the BBB (Banks 2006). IL-1β, IL-6, TNFα, and other 
cytokines, each have their own transporters (Banks, Niehoff, and Zalcman 2004; Banks, Kastin, 
and Durham 1989). Transporters for cytokines are affected by physiological and disease states, 
hereby affecting the rate at which cytokines are transported across the BBB (Ning Quan and 
Banks 2007; Banks et al. 2001). Limited research has attempted to identify the specific 
contribution of these transport systems in cytokine trafficking and consequential cytokine 
induced behaviour. IL-1β induced impairment to learning was dependent on BBB transport 
(Banks et al. 2001), and LPS-induced dopaminergic neuron damage in the substantia nigra was 
dependent on TNFα transport (Qin et al. 2007).  
4. HPA-axis Intermediates 
Prostaglandins and COX enzymes are important for febrile responses, and these molecules 
can also be modulated from the CVOs. For instance, LPS stimulated increase in COX-2 
correlates with the febrile responses (Cao et al. 1997), and prostaglandins released from brain 
endothelial cells mediate fever induced by LPS (W. Inoue et al. 2002). Lesioning of a CVO close 
to the thermoregulatory center of the hypothalamus blocks cytokine induced fever (Zeisberger 
and Merker 1992). Activation of IL-1 receptors from macrophages and endothelial cells by 
circulating cytokines results in the local production of prostaglandin E2 (PGE2) (Konsman et al. 
2004). Specifically, compounds act on neuronal Prostaglandin E receptor 1 (EP1) and 
Prostaglandin E receptor 3 (EP3) in the hypothalamic area involved in body temperature 
regulation. In particular, the paraventricular nucleus (PVN) and medial preoptic area (MPA) 
(Oka et al. 2000; Serge Rivest 2001). These are believed to be the primary mediators of fever 
and activation of the HPA axis, since pretreatment with inhibitors of prostaglandin-synthesizing 
enzyme COX-2 attenuates these responses (Cao et al. 1997; Parsadaniantz et al. 2000). EP 
receptors are prerequisite for LPS-induced activation of HPA axis activity and ensuing febrile 
responses (Matsuoka et al. 2003) 
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 To date, the full contribution of each pathway that facilitates immune-to-brain signalling is 
not fully understood. Furthermore, each individual proinflammatory cytokine appears to have 
unique contributions to the ensuing signalling cascade in sickness behaviour. For instance, both 
IL-1β and TNFα appear to be sufficient to trigger significant sickness characteristics on their 
own. IL-1β delivery to the brain that is dependent on neural transmission or any of the humoral 
routes triggers characteristic sickness behaviour (Anisman, Gibb, and Hayley 2008; Churchill et 
al. 2006; Marquette et al. 2003) (R.-M. Bluthé, Kelley, and Dantzer 2006; Layé et al. 1994). In 
this case, knockout of the IL-1R1 receptor in mice prevents characteristic social withdrawal and 
anorexia, suggesting IL-1β alone is sufficient to induce sickness. However, in these same mice 
with knockout of IL-1R1 (the receptor for IL-1β) sickness behaviour is restored by peripheral 
injection of LPS. This suggests that at least one of the other cytokines is also involved in 
triggering sickness. Indeed, TNFα delivered i.c.v. replicates the effects of IL-1β, which is then 
blocked by a TNFα antibody (R.-M. Bluthé, Layé, et al. 2000), suggesting TNFα is also 
sufficient to induce sickness on its own. In fact, TNFα delivery to the brain by numerous routes 
induces the full spectrum of sickness (R.-M. Bluthé, Kelley, and Dantzer 2006; R.-M. Bluthé, 
Layé, et al. 2000; Churchill et al. 2006; Marquette et al. 2003; Park et al. 2011) as does TNFα 
i.p. administration (R. M. Bluthé et al. 1994). In contrast to IL-1β and TNFα, IL-6 by itself does 
not induce behavioural symptoms of sickness. It is likely that IL-6 mediates behaviour indirectly 
by modulating the levels of IL-1β and TNFα, since sickness behaviour and cognitive impairment 
are less noticeable in IL-6 deficient mice, which is correlated with a reduced expression of the 
other two cytokines (R.-M. Bluthé, Michaud, et al. 2000, 6; Sparkman et al. 2006, 6). 
Furthermore, IL-6 KO mice display less time of immobility in an observation task, weakened 
social withdrawal, and less severe anorexia, after i.c.v. administration of LPS or IL-1β, compared 
to IL-6 homozygous controls (R.-M. Bluthé, Michaud, et al. 2000). It must also be noted that IL-
6 does trigger fever and activation of the HPA axis when administered centrally (Lenczowski et 
al. 1999). In conclusion, IL-1β and TNFα are necessary for sickness behaviour, but one may 
compensate for the other. IL-6 is not necessary for sickness behaviour, but does lessen the 
severity of behavioural changes when not present, and is sufficient to trigger febrile responses 
and HPA axis activation. Whether neurons or glia cells such as microglia trigger and maintain 
ensuing sickness behaviour is unknown (Robert Dantzer et al. 2008). 
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1.3 Microglia – the Innate Immune Cells of the Brain 
1.3.1 Classic Roles in Inflammation  
Microglia, the innate immune cells of the brain, have long been known to detect and 
phagocytose infectious agents, engulf apoptotic cells and cellular debris, and promote 
inflammation (Kettenmann et al. 2011; Ransohoff and Perry 2009). As such, they have been 
implicated in several pathological conditions including Alzheimer’s and Parkinson’s disease, 
Prion disease, and ALS (Perry and Holmes 2014; Tang and Le 2016). Emerging research also 
implicates microglia in neuropsychiatric disorders (Blank and Prinz 2013). Microglia phenotypes 
in the CNS have classically been classified as either M1 or M2. This is a simplified model used 
to distinguish microglia between proinflammatory (M1) and anti-inflammatory (M2) dominance. 
For example, the M1 microglia are considered proinflammatory, and are recruited to sites of 
inflammation where they release proinflammatory cytokines including tumor necrosis factor 
(TNF)-α, interleukin (IL)-1β, superoxide, nitric oxide (NO), and reactive oxygen species (ROS). 
The M1 phenotype is associated with neurodegenerative disease as well as metabolic disease 
(Tang and Le 2016, 1). On the other hand, M2 microglia are classified as either “alternative 
activation” or “acquired activation” (Wilcock 2010; Colton 2009). Alternative activation 
promotes anti-inflammatory processes and tissue repair and is triggered by IL-4 (Ponomarev et 
al. 2007), while acquired activation is also intended to alleviate inflammation but is induced by 
phagocytosis of apoptotic cells and exposure to IL-10 (Sawada et al. 1999).   
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Microglia have long been considered likely cellular intermediates fueling the response to 
systemic inflammation and sickness (Sierra et al. 2014). They are known to drive inflammatory 
responses by releasing cytokines and other molecules (Hanisch and Kettenmann 2007; Nayak, 
Roth, and McGavern 2014; Ransohoff and Perry 2009; Salter and Beggs 2014), suggesting that 
microglia are well positioned to interpret incoming immune signals and help to drive ensuing 
neuroinflammation and sickness behaviour. In line with this, when the brain recognizes increased 
cytokine levels generated by LPS,  microglia responds by robustly increasing production of 
proinflamamtory cytokines (Figure 1.2) (Baumann and Gauldie 1994; R. M. Bluthé et al. 1994; 
Robert Dantzer and Kelley 2007; G. Luheshi et al. 1996; N. Quan, Whiteside, and Herkenham 
1998) (Norden et al. 2016). Furthermore, the microglia inhibitor minocycline prevents LPS-
induced cytokine production in the brain (H.-L. Wang et al. 2016; Yoon, Patel, and Dougherty 
2012).  
Despite the above evidence, the roles that microglia play in controlling sickness behaviour are 
not fully understood. This is due in large part to the technical difficulty in targeting microglia in 
the living brain without inadvertently affecting other cell types. Moreover, inhibition or 
elimination of microglia may disturb microglia-astrocyte-neuronal crosstalk in complex ways. It 
has become increasingly clear that microglia function must be studied in vivo, preferentially 
using specific techniques which exclusively target microglia and do not modulate the 
environment surrounding microglia cells. These cells are highly reactive to signals and cues in 
their environment. Indeed, when isolated in culture, microglia display characteristics indicating a 
proinflammatory phenotype in the absence of experimental activation (Brawek et al. 2017). 
1.3.2 Interactions with Neurons 
Under physiological (non-inflammatory) conditions in vivo, emerging evidence show that 
microglia dynamically interacts with neurons (Wake et al. 2009). Two-photon imaging in a 
double transgenic mouse line simultaneously labelling microglia and neuronal structures 
revealed microglia processes make brief, repetitive contacts with presynaptic boutons that last 
about 5 minutes. These interactions are experience dependent, as modulation of the physiological 
conditions of the brain via binocular eye enucleation or reduction in body temperature, reduced 
the frequency of microglia contacts (Wake et al. 2009) In line with this, other research has shown 
that microglia interactions with neurons are experience dependent, since altering neuronal 
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activity changed functional microglia properties (Tremblay, Lowery, and Majewska 2010; Wake 
et al. 2009).  
Some of these microglia-neuron interactions are necessary for healthy brain development. 
For example, it has long been known that microglia phagocytosis is an important property in 
response to brain pathology, however, under healthy conditions the microglia engulfment of 
synaptic structures plays important roles in development (Rosa C. Paolicelli et al. 2011; Schafer 
et al. 2012). During a period of synaptic maturation in mice, electron microscopy and double 
immune-gold labelling identified synaptic proteins within GFP-positive microglia, suggesting 
microglia engulfment of synaptic structures. A reduction of specific microglia GPCR CX3CR1 
resulted in a reduction in their synaptic pruning and consequential decrease in the ratio of 
sEPSC/mEPSC, indicative of immature network connectivity (Rosa C. Paolicelli et al. 2011). In 
recent years, other mechanisms of microglia in the regulation of synaptic plasticity have been 
identified. This includes the classical complement cascade, which microglia presumably use to 
label dysfunctional circuitry (Schafer et al. 2012). Microglia regulation of plasticity also includes 
modulation of NMDA receptors or AMPAR, which influence long-term potentiation (LTP) and 
long-term depression (LTD) (Zhang et al. 2014; Pfeiffer, Avignone, and Nägerl 2016). Microglia 
also affect neural networks through the release of factors with transmitter, trophic or 
neuroprotective properties, including TNFα, nitric oxide (NO), or ATP and glutamate 
(Kettenmann et al. 2011; Lewitus et al. 2016).  
One prominent example of microglia-neuron communication occurs by the release of 
brain-derived neurotrophic factor (BDNF) from microglia. In one instance, microglia release of 
brain-derived neurotrophic factor (BDNF) increases neuronal tropomyosin-related kinase 
receptor B phosphorylation, implicating microglia in another key mechanism of synaptic 
plasticity (Parkhurst et al. 2013). This triggered learning-dependant synaptic growth which 
correlated with motor learning in a rodarod task (Parkhurst et al. 2013).  Microglia BDNF release 
has other implications, including the initiation of neuropathic pain/GABAergic signalling (Coull 
et al. 2005; Trang, Beggs, and Salter 2011) or neuroprotection (H. Noda et al. 2013).  
On the other hand, synaptic pruning by microglia may be associated with brain 
pathology. Synapse loss is an early hallmark of AD pathology, and localization and expression of 
complement - which acts as a trigger for microglia engulfment -is upregulated in the AD brain 
(Benoit et al. 2013).  For instance, C1q, the initiating protein of the complement cascade and 
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microglia engulfment, is increased and associated with synapses prior to onset of plaque 
progression. Complement C3 and microglia complement receptor CR3 also regulates their 
phagocytosis, and inhibition of these proteins reduces the number of phagocytosing microglia 
and frequency of synapse loss (Hong et al. 2016). Indeed, this microglia engulfment of synaptic 
material is dependent on microglia complement receptor CR3, and this is initiated when exposed 
to soluble Aβ oligomers (Hong et al. 2016), suggesting microglia engage in excessive pruning of 
synapses during AD progression. 
Importantly, communication with neurons is bidirectional, as microglia express receptors for 
various neurotransmitters and neuromodulators both in the form of metabotropic G-protein 
coupled receptors (GPCRs) and ionotropic receptors (Kettenmann et al. 2011). GPCRs are of 
particular interest, since they are important modulators of neuroinflammation, 
neurodegeneration, and behaviour (Kettenmann et al. 2011). Here, I will discuss prominent 
GPCRs expressed by microglia, with relevance to calcium signalling and neuroinflammation. I 
will also summarize research of microglia calcium response to LPS.   
1.3.3 GPCRs expressed in microglia 
1. Fraktalkine Receptor (Cx3Cr1) 
A large body of literature supports fraktalkine signaling between neurons and microglia 
to be a major contributing factor to a wide range of microglia properties (figure 1.3) (Rosa 
Chiara Paolicelli, Bisht, and Tremblay 2014) This includes their function during normal 
physiology, but also their migration and dynamic surveillance of their environment, neural 
plasticity, functional brain connectivity, hippocampal neurogenesis, and behavioural outcomes 
(Bachstetter et al. 2011, 1; Milior et al. 2016; Rogers et al. 2011; Zhan et al. 2014). Fraktalkine 
signalling involves the soluble ligand CX3CL1, otherwise known as fraktalkine, and the 
CX3CR1 receptor exclusively expressed by microglia and monocytes (Milior et al. 2016). The 
fraktalkine receptor CX3CR1 is a Gi-protein coupled receptor, which inhibits the production of 
cAMP, triggering a variety of intracellular signalling cascades (Chandrasekar et al., 2003). 
However, the fraktalkine receptor also mobilizes intracellular calcium (Al-Aoukaty et al. 1998). 
Experiments ex vivo using time-lapse confocal imaging showed that microglia motility is 
reduced in CX3CR1 deficient microglia (Liang et al. 2009). In these experiments, CX3CR1 
deficiency resulted in a significant reduction in microglia process movement both under normal 
physiology as well as during tissue injury induced by focal laser application (Liang et al., 2009). 
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Several studies have also reported an impairment in synaptic transmission in Cx3Cr1 KO mice 
(Hoshiko et al. 2012; Rosa C. Paolicelli et al. 2011; Ueno et al. 2013). At the behavioural level, 
Cx3Cr1 KO mice show deficit in motor learning that is paralleled by an impairment in long-term 
potentiation (LTP) of synaptic transmission studied in ex vivo, compared to wildtype controls 
(Rogers et al. 2011). Animals also failed to show associative learning, and had impairments in 
the  water maze task. Interestingly, the cognitive deficits observed in CX3CR1 knockout mice 
was reversed by administration of IL-1RA into the hippocampus, an antagonist for 
proinflammatory cytokine IL-1β (Rogers et al. 2011). In regards to neuroinflammation, it has 
been shown with a mouse model of Alzheimer’s disease (AD) that Cx3Cr1 may have protective 
roles (Lee et al. 2010). In contrast to this finding, another study investigating neuroinflammation 
and AD pathology found an increase in mRNA and protein levels of CX3CR1 to be toxic (Wu et 
al. 2013). In both cases, neuroinflammation was assessed by levels of cytokines TNFα and IL-
1β, which were differentially modulated by expression levels of the fraktalkine receptor. These 
opposing roles of CX3CR1 have been replicated in many neuroinflammatory models, showing 
either a decrease (Dénes et al. 2008, 1; Donnelly et al. 2011; Fuhrmann et al. 2010) or increase 
(Cardona et al. 2006; Cho et al. 2011; Lee et al. 2010) of microglia activity and neurotoxicity. 
These results suggest that neuron-microglia signalling mediated by CX3CR1 plays important 
roles in neuroinflammation and pathology, but has differential effects on microglia inflammatory 
properties which require further investigation.  
2. Purinergic Receptors (P2Y) 
Metabotropic purinergic receptors mediate phagocytotic function and migration of 
microglia. The P2Y6 receptor is linked to Gq/11 proteins and regulates intracellular Ca
2+
 stores 
(Hidetoshi, Makoto, and Inoue 2012, 6).  Extracellular uridine-5’-triphpshate (UTP) and its 
metabolite uridine diphosphate (UDP), which can leak from damaged plasma membrane, serves 
as neuronal damage signal by acting on P2Y6 receptor in microglia (Koizumi et al. 2007). 
Research suggests this microglia receptor in particular also mediates astrocyte properties under 
LPS-induced inflammatory conditions. In LPS treated co-cultures of microglia and astrocytes, 
UDP agonist induced microglia release of nitric oxide. NO release by microglia has been known 
to modulate astrogenesis, at least in the hippocampus (Béchade et al. 2011). The P2Y6 induced 
release of NO by microglia caused astrocyte apoptosis, herby preventing excessive astrogliosis 
during neuroinflammation (Quintas et al. 2014, 6). This inhibitory effect of P2Y6 was abolished 
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by blockage of Gq downstream pathway PLC-PKC (Quintas et al. 2014).  
The P2Y12 receptor for ATP and ADP, acts as a ‘find me’ signal which triggers 
microglia chemotaxis (Honda et al. 2001). Although P2Y12 is a Gi-coupled receptor, it too has 
intracellular calcium signalling properties that are dependent on the PLC pathway. Indeed, 
studies have confirmed ATP triggers ruffling of microglia processes, and this is dependent on 
P13K and PLC intracellular calcium signalling (Irino et al. 2008; Ohsawa et al. 2010), and can 
be triggered by neuronal NMDA activation in vivo (Dissing-Olesen et al. 2014). A failure of 
phagocytosis or chemotaxis is likely to indirectly modulate levels of neuroinflammation in 
certain circumstances (Hidetoshi, Makoto, and Inoue 2012). Importantly, both receptors 
discussed here influences the levels of cytokine release following LPS. For instance, both ATP 
and UTP supressed release of proinflammatory cytokine TNFα from LPS-stimulated cultured 
microglia, with ATP eliciting a stronger effect than UTP (Ogata et al. 2003). Other studies have 
shown P2Y-mediated modulation of TNFα, IL-1β, IL-6, IL-12, and IL-10, in LPS-activated 
microglia and LPS-activated rat microglia (Lambert et al. 2010; Ogata et al. 2003; Sperlágh and 
Illes 2007). 
 
3. Other GPCRs 
Microglia express a host of other GPCRs with calcium signalling properties, albeit their roles 
are not fully understood. 
Glutamate mGluR 
Selective activation of Gq-coupled metabotropic glutamate receptor 5 (mGluR5) by (RS)-2-
chloro-5-hydroxyphenylglycine(CHPG) reduced microglia activation in culture in response to 
LPS, marked by reduced ROS, nitric oxide, and TNFα production (Byrnes et al. 2012). 
Interestingly, this neuroprotective effect was abolished by inhibitors of PLC and PKC, 
suggesting a specific role of microglia calcium signalling in response to neuroinflammation. 
Although microglia express a host of other mGluR receptors, including group 2 (mGluR2, 
mGluR3) and group 3 (mGluR4-6 and -8), which modulate microglia inflammatory responses, 
these are not predicted to modulate Gq-signalling or intracellular calcium signalling in microglia 
(Pocock and Kettenmann 2007). 
Muscarinic Acetylcholine (mAChRs) 
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It is worth noting that a subpopulation (11-16%) of microglia identified with FACS analysis 
express muscarinic acetylcholine receptor M3. The M3 receptor agonist carbachol triggered a 
transient increase in intracellular Ca2+ (Whittemore et al. 1993). This carbachol-sensitive 
population increased in microglia isolated from tissue of mouse models for stroke as well as 
Alzheimer’s disease, to 60% and 25%, respectively (Pannell et al. 2016).  
Bradykinin 
Kinins and bradykinin (BK) are active peptides that are up-regulated in response to 
inflammation in the periphery aswell as the central nervous system. In cultured microglia, 
bradykinin (BK) (B1 and B2) are linked to Ins(1,4,5)P3 signalling, leading to increased 
intracellular calcium and activation of Ca
2+
-dependent K
+
channels via Gq signalling (M. Noda et 
al. 2003). BK increases microglia motility and induced release of NO and PGE2 (Asraf et al. 
2017; M. Noda, Kettenmann, and Wada 2006). However, it can also reduce LPS-induced release 
of TNFα and IL-1β (M. Noda, Kettenmann, and Wada 2006). 
 In conclusion, it is evident that microglia express a host of GPCRs which become activated 
by external cues and neurotransmitters, and consequentially modulate microglia properties, 
including inflammatory responses. However, the problem remains of studying microglia by 
isolating them from brain tissue or culturing procedures, since this transforms them into an 
activated phenotype. This especially holds true when analyzing calcium signals, since baseline 
calcium levels increase upon isolation. Many of the studies discussed here pointing to the 
important of microglia GPCRs, use cultured microglia, meaning we know next to nothing about 
the roles of these receptors in “resting” microglia. There is a need for novel techniques which 
target microglia signalling without inadvertently modulating the microglia environment.  
1.4 DREADDs 
New approaches to specifically target microglia without inadvertently modulating the 
microglia environment are required. Much of the existing literature on microglia roles is based 
on the use of non specific techniques. For instance, minocycline is a tool commonly used to 
study microglia function, but its exact mechanism is unknown. Studies indicate MAP kinase and 
NFκB inhibition in primary microglia and cell cultures mechanism (Amin et al. 1996; 
Nikodemova, Duncan, and Watters 2006). In addition, it likely abrogates microglia expression of 
CD11b and MHC II via protein kinase- dependent mechanism (Amin et al. 1996; Nikodemova, 
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Duncan, and Watters 2006). However, minocycline is a tetracycline antibiotic  which also exerts 
non-antiobiotic effects, including anti-apoptotic activities, inhibition of proteolysis, anti-oxidant 
activity, and inhibition of several enzyme activities (Garrido-Mesa, Zarzuelo, and Gálvez 2013) 
Recently, research has shown significant effects of minocycline on neuronal functioning, 
including changes to generation of reactive oxygen species (ROS) and mitochondrial dynamics 
(Dai et al. 2017). Based on the reactivity of microglia in vivo, this is likely to inadvertently 
modulate their functioning.  
 Microglia are sensitive enough to detect external changes in the host organism’s 
environment. For instance, sensory loss is another environmental factor that changes neuronal 
properties in the living brain, and accordingly, alters microglia responses (Tremblay et al. 2012). 
Likewise, housing conditions that affect the psychological state of the animal also modulates 
microglia functioning. For instance, animals housed in an enriched environment experience a 
reduction in levels of neuroinflammation and microglia activation (Briones, Woods, and 
Rogozinska 2013; Xu et al. 2016). Inversely, animals housed in an impoverished environment 
reveal exacerbated markers of neuroinflammation (Ji et al. 2017). To summarize, nonspecific 
techniques which modulate the microglia environment and physiological conditions of the brain 
are likely to inadvertently alter microglia functioning. 
One possible solution to targeting microglia specifically in the living brain is the use of 
DREADDs (designer receptors exclusively activated by designer drugs), engineered muscarinic 
receptors which no longer have affinity for acetylcholine (Alexander et al. 2009; Ferguson and 
Neumaier 2012). DREADDs can be activated by a number of otherwise inert molecules, such as 
clozapine-N-oxide (Whissell, Tohyama, and Martin 2016). Indeed, DREADDs have been used to 
tease out novel neuronal functions, and some glia functions (Ferguson and Neumaier 2012; 
Scofield et al. 2015; Zhu et al. 2016), but have had limited use in microglia (Grace et al. 2018). 
For instance, Ferguson and colleagues used viral vectors to trigger DREADD expression to 
specific cell populations in the striatum. They found that transiently decreasing activity of 
striatopallidal neurons in rats during repeated amphetamine exposure facilitated the development 
of behavioral sensitization (Ferguson and Neumaier 2012). This suggests DREADDs can be an 
effective tool to tease out underlying mechanisms of behavioural change. Scofield and 
colleagues also used viral vector to express DREADD receptor in astrocytes in the nucleus 
accumbens core (NAcore), to reveal a role of glutamate gliotransmission in cocaine seeking 
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behaviour (Scofield et al. 2015). Of particular interest for this study, Grace and colleagues also 
used viral targeting to express Gq- or Gi- DREADD in spinal microglia in vivo or in vitro under 
the CD68 microglia/macrophage promoter. This particular study suggested that in vivo 
stimulation of spinal microglia Gq-DREADD is sufficient and necessary for allyodynia induced 
by peripheral nerve injury (Grace et al. 2018).  
In comparison to viral targeting to express DREADDs, tamoxifen inducible Cre 
responsive mice to selectively drive expression of DREADD in microglia is another promising 
option. CX3CR1 is a microglia/monocyte specific gene which has successfully been used to 
specifically target microglia in the brain (Parkhurst et al. 2013). We choose CX3CR1 to drive 
Cre recombinase and DREADD expression, instead of the CD68 marker used in the Grace study, 
since CD68 is a microglia marker often associated with activated or inflammatory phenotypes 
and elevated antigen presentation (Song, Lee, and Schindler 2011). This poses the risk of 
DREADD targeting being biased towards a subset of microglia. Importantly, our chosen 
technique avoids the administration of viral vectors, which have previously been shown to 
trigger innate immune responses and consequential inadvertent activation of microglia  (Sakurai 
et al. 2008). DREADDs are engineered to mimic GPCR signalling, which regulates many 
important microglia properties, as previously mentioned. DREADDs are a unique tool to 
investigate microglia calcium signalling, since neither specific types of GPCRs are expressed 
exclusively in microglia, nor are there drugs that can activate only specific subtypes of GPCRs in 
microglia to investigate their roles in neuroinflammation.  
Our group previously generated mice expressing the h3MDq DREADD in microglia (Fig. 
3.1A). Primary microglia cultures obtained from these mice were treated with the active 
tamoxifen metabolite 4-OHT (Fig. 3.1B). Our unpublished data show that of Iba1-positive cells 
~35% expressed h3MDq detected using the HA tag located at plasma membrane (Fig. 3.1B, C). 
In these cultures, only few cells were GFAP positive (astrocytes), and they did not express 
hM3Dq (Fig. 3.1D). CNO (3 µM) induced the expected increase in intracellular Ca
2+
 in the 
presence or absence of extracellular Ca
2+
 indicating the mobilization from intracellular Ca
2+
 
stores (Pei et al. 2008; Urban and Roth 2015). We identified microglia expressing hM3Dq by the 
co-expression of mCitrine (Fig. 3.1E, G, right panels, green). Microglia obtained from 
CX3CR1
CreER
 -hM3Dq mice but which were not treated with 4-OHT did not respond to CNO, but 
still responded to ATP (Fig. 3.1F, H). Predictably, these cells did not exhibit mCitrine, as shown 
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by the absence of green/yellow cell, when imaged with the same parameters as 4-OHT treated 
cultures (Fig. 3.1F, H, right panels). These experiments together indicated that hM3Dq 
expression in microglia allows for manipulation of Ca
2+
 signalling pathways by using CNO, 
which in our hand could rapidly  activate intracellular Ca
2+
 signalling as previously reported 
(Alexander et al. 2009).  
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Figure 1.2 
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Figure 1.2 Primary Cx3cr1
CreER
-hM3Dq microglia express inducible DREADD receptors 
that trigger Ca
2+
 signalling in response to CNO. (A) Schematic of tamoxifen-inducible Cre 
recombinase driving expression of hM3Dq in cx3cr1+ cells. (B) Representative images of 
immunostaining for HA-tag (red) and Iba1 (green) in microglia-enriched culture treated with 4-
OHT. (C) Quantification of hM3Dq-positive microglia in control and 4-OHT-treated cultures. 
***: p<0.001. (D) Representative image of immunostaining for HA (red) and GFAP (green, 
astrocytic marker) in microglia-enriched culture treated with 4-OHT. (E-H) Calcium signalling 
in Rhod-2 loaded Cx3cr1
CreER
-hM3Dq microglia cultures. (E) Kinetics of relative Rhod-2 
fluorescence in cells in response to 3 µM CNO, 1 mM ATP, or 2 µM ionomycin (left panel) in 4-
OHT treated cultures in calcium-enriched medium. Snapshot of the imaging field before the 
kinetics (right) in transmitted light, green (mCitrine) and red (Rhod-2) channels. (F) Same as (E) 
for cultures not treated with 4-OHT. (G) Kinetics of relative Rhod-2 fluorescence in cells in 
response to 3 µM CNO, 1 mM ATP, or 10 µM thapsigargin (left panel) in 4-OHT treated 
cultures in calcium-free medium. Snapshot of the imaging field before the kinetics (right) in 
transmitted light, green (mCitrine) and red (Rhod-2) channels. (H) Same as (G) for cultures not 
treated with 4-OHT. At least 3 cultures were imaged for each condition. Kinetics from all cells in 
the imaging field were analyzed.  *: p<0.05.  
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Based on this preliminary data, the hM3Dq-microglia mouse model is a promising tool to 
investigate microglia responses in sickness behaviour. To this point, we aimed to investigate the 
consequences of hM3Dq signalling in microglia in vivo under healthy condition and during 
inflammation.  
1.5. Rationale, Hypothesis, Aims 
1.5.1 Rationale: Microglia roles in sickness 
Peripheral inflammatory driven immune signals induce sickness behaviour by triggering a 
secondary neuroinflammatory response in the brain. Microglia, the immune cells of the brain, 
orchestrate neuroinflammation and have long been thought to be important for sickness behavior. 
However, their precise roles in sickness behaviour remain obscure due to their reactivity to the 
physiological conditions of the brain as well as their complex interactions with neurons in vivo. 
1.5.2 Hypothesis 
Microglia GPCR signalling contributes to neuroinflammatory and sickness behaviour during 
systemic inflammation.  
1.5.3 Aims 
1. Complete characterize of the Cx3cr1
CreER
-hM3Dq mice and determine potential 
microglia specific expression of hM3Dq, and CNO-mediated Ca
2+
 dynamics. 
2. To investigate the behavioural and neurochemical changes that occur in response to 
microglia-hM3Dq signalling in vivo.  
3. To investigate the behavioural and neurochemical changes that occur in response to 
microglia-hM3Dq signalling in vivo following PS-induced systemic inflammation.  
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Chapter 2 
2. Materials and Methods 
2.1 Animals 
CX3CR1
CreER
 mice (Jackson Laboratory, B6.129P2(Cg)-Cx3cr1tm2.1(cre/ERT2)Litt/WganJ) 
expressing tamoxifen-activated Cre-recombinase and EYFP in microglia in the brain (Parkhurst 
et al. 2013), were obtained from Jackson Laboratories. R26-hM3Dq/mCitrine (Jackson 
Laboratory, B6N;129-Tg(CAG-CHRM3*,-mCitrine)1Ute/J) mice expressing  a Cre responsive 
hM3Dq N-terminal HA-tag were previously described (Zhu et al. 2016) and they were gently 
donated by Brian Roth. To produce mice expressing microglia-specific hM3Dq, CX3CR1
CreER
 
mice were crossed with R26-hM3Dq/mCitrine, and subsequently treated with tamoxifen. We 
wait >30 days after tamoxifen injection, based on the fact that microglia and other CX3CR1
+
 
cells have substantially different turnover rates and regenerate from different precursor 
populations (Fogg et al. 2006; van Furth and Cohn 1968). We expect that microglia would 
undergo recombination that persists once tamoxifen has ceased (Parkhurst et al. 2013). In 
comparison, peripheral CX3CR1
+
 cells would initially express hM3Dq but subsequently be 
replaced by bone marrow derived Cx3cr1
- 
cells not forgoing recombination. All mice shown are 
male, and 3-5 months of age at the time of experimentation. All procedures were conducted in 
accordance with the guidelines of the Canadian Council of Animal Care and approved by the 
University of Western Ontario Animal Use Subcommittee (protocol 2016-103 and 2016-104). 
The study also complied with the ARRIVE guidelines (Animal Research: Reporting in Vivo 
Experiments). Animals had access to food and water ad libitum, and were maintained on a 12 
h/12 h light-dark cycle.   
2.2 Tamoxifen  
Tamoxifen (Sigma, cat#T56648) was dissolved at 100 mg/ml in 10% ethanol/90% corn oil by 
heating to 55 °C and vortexing. Aliquots were kept at -20 °C for no more than 1 week. 
Immediately before use, the aliquots were diluted to 20 mg/ml in corn oil and injected 4 µl/g 
body weight. To induce DREADD expression, tamoxifen (80 mg/kg i.p.) was injected once per 
day for 5 consecutive days. For cell culture assays, tamoxifen active metabolite 4-
hydroxytamoxifen (4-OHT, Sigma, cat#H6278) was used instead of tamoxifen 4-OHT was 
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dissolved in 100% ethanol to final concentration 14 mM, and stored aliquoted at -80 °C. Before 
use, the aliquots were diluted to 5 µM in the culture medium. E. coli 0111:B4 LPS (Sigma-
Aldrich, 297-473-0) was aliquoted at 5 mg/ml and stored at -80 °C until used. Clozapine N-
Oxide (CNO, Tocris, cat#4936) was dissolved to 1 or 5 mg/ml in dimethylsulfoxide (DMSO) 
and stored aliquoted at -20 °C. Calcium dye Rhod-2 AM (Abcam, cat#ab142780) was diluted to 
1 mM in DMSO and stored aliquoted at -20 °C. Store-operated Ca
2+
 inhibitor (SOCE) SKF-
96365 (Santa Cruz, cat#130495-35-1) was diluted in water. 
2.3 Primary Microglia Cultures  
Mixed glia cultures were prepared from the P0-P2 mice following established procedure 
(McCarthy and Jean De Vellis 1980)(McCarthy and Jean De Vellis, 1980) with small 
modifications. Briefly, extracted forebrains were dissociated in DMEM/F12, supplemented with 
1 mM KCl, 10% heat-inactivated fetal bovine serum (both ThermoFisher) and 1× 
penicillin/streptomycin (Sigma). Cells were plated on 75-cm
2
 tissue culture flasks coated with 
poly-D-lysine and incubated at 37 °C in 5% CO2 atmosphere. The culture medium was changed 
after 3 days and then every 5 days until confluency (12–18 days in vitro).  
To obtain pure microglia cultures flasks of mixed glial cultures were shaken at 200 rpm 
for 2 h at 37 °C. Floating microglia were collected by centrifugation (380g for 10 min), and 
seeded at ~1×10
5
 cells/ml on poly-D-lysine coated dishes containing 50% old/50% new media. 
In the next day culture medium was supplemented with 5 µM 4-OHT and incubated for 48 h for 
optimal induction of hM3Dq expression. Approximately 5×10
5
 cells were obtained per brain 
used. 
Immunocytochemistry was done on microglia plated on glass coverslips as described 
previously (Ostapchenko et al. 2013). After 48-hour incubation with 5 µM 4-OHT or vehicle, 
cultures were rinsed with ice-cold PBS and fixed with 4% paraformaldehyde (PFA) in PBS. 
After permeabilization with 0.5% Triton X-100 and blocking with 5% bovine serum albumin 
(BSA)/0.1% Triton X-100, cultures were incubated with primary antibodies (anti-HA-tag for 
hM3Dq, BioLegend, cat#901501; anti-Iba1, marker for microglia, Abcam, cat#ab5076; anti-
GFAP, marker for astrocytes, Abcam, cat#ab7260) overnight at 4 °C, followed by 1-hour 
incubation with Alexa Fluor 555 goat anti-mouse (1:1000, cat#A32727) and Alexa Fluor 633 
goat anti-rabbit (1:1000, cat#A-21070, both Thermo Fisher) secondary antibodies and Hoechst 
33342. Coverslips were then mounted on glass slides using Immumount (Thermo) medium and 
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imaged using an FV1000 confocal microscope (Olympus) equipped with a 20x/0.75, 30x/1.05 or 
60x/1.35 objective. At least 3 cultures were imaged for each condition and staining markers, with 
at least 6 images randomly taken over a coverslip. Images were analyzed using ImageJ (NIH, 
Bethesda, MD) Cell Counter plugin. 
2.4 Electrophysiology   
Male mice were deeply anesthetized in a chamber saturated with isoflurane, and once spinal 
reflexes were absent, were decapitated. The brains were quickly removed and placed in ice cold 
slicing solution containing (in mM) 87 NaCl, 2.5 KCl, 0.5 CaCl2, 7 MgCl2, 25 NaHCO3, 25 D-
glucose, 1.25 NaH2PO4 and 75 sucrose, constantly bubbled with 95% O2/5% CO2. Coronal 
brain sections (300 µm) were cut using a vibratome (VT-1200, Leica Biosystems). Hippocampal 
regions were trimmed and transferred into an incubation chamber containing artificial 
cerebrospinal fluid (aCSF) consisting of (in mM) 126 NaCl, 2.5 KCl, 26 NaHCO3, 2.5 CaCl2, 
1.5 MgCl2, 1.25 NaH2PO4 and 10 D-glucose, saturated with 95% O2/5% CO2 and maintained 
at 35 °C. Slices were recovered at this temperature for 45 min, and thereafter were kept at room 
temperature. For electrophysiological recordings, slices were transferred to a recording chamber 
superfused with aCSF (1.5-2.0 ml/min, 27-30 °C). Recording pipettes were made from 
borosilicate glass (BF120-69-15, Sutter Instruments) pulled in a horizontal puller (P-1000, Sutter 
Instrument) with an open tip resistance between 3.0-5.0 MΩ, filled with an internal solution 
containing (in mM) 116 K-gluconate, 8 KCl, 1 K2-EGTA, 10 HEPES, 2 MgCl2, 4 K2ATP and 
0.3 Na3GTP. In some experiments, BAPTA-K4 (10 mM) was added to the internal solution. 
Osmolarity was 285-290 mOsm, pH 7.2-7.4. CA1 pyramidal neurons were visually identified for 
their large cell soma using an upright microscope equipped with infrared differential interference 
contrast optics (BX 51WI, Olympus). In voltage-clamp configuration, postsynaptic neurons were 
held at −68 mV and EPSCs were pharmacologically isolated with the GABAA receptor 
antagonist picrotoxin (100 µM) and the glycine receptor antagonist strychnine (0.5 µM) added to 
the aCSF. Tetrodotoxin (TTX, 0.5 µM) was added to block voltage gated Na+ channels to record 
miniature excitatory postsynaptic currents (mEPSCs). Access resistance was monitored 
throughout the recordings and if the value exceeded 20 MΩ the recordings were rejected. 
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2.5 Immunohistochemistry 
Initial immunohistochemistry experiments in primary cultured microglia was performed by 
Valeriy Ostapchenko. Quantification of Iba-1+ microglia/hM3Dq+ cells was performed by 
Muhammed Al-Onaizi. Subsequent experiments re analyzing Iba1+/hM3Dq+ cells, and 
microglia morphological dynamics, used the same perfusion and slice preparation techniques, as 
follows. Mice were initially perfused with 200mL of cold PFA, and mouse brains were extracted 
from mice injected with tamoxifen or vehicle as described previously (Ostapchenko 2015). After 
incubation in PFA for 24 h, brains were sectioned using a VT 1200 S vibratome (Leica). Staining 
for Iba1 (1:1000, WAKO, cat#CTK6675), HA (1:1000, BioLegend, cat#901501), GFAP 
(1:1000, Abcam, cat#ab7260) or NeuN (1:1000, Cell Signalling, cat#D3S3I) was performed as 
described previously (Kolisnyk et al. 2016) using Alexa Fluor 555/633-tagged secondary 
antibodies (ThermoFisher) and Hoechst 33342. Sections were mounted on glass slides using 
Fluorescent-G mounting medium (Electron Microscopy Sciences, cat#17984-25) and imaged 
using an SP8 confocal microscope (Leica) equipped with a 20x/0.75 dry or a 40x/1.3 oil 
objective. At least 4 forebrain sections were imaged for each animal for each condition, with at 
least 6 fields imaged for each section. Images were analyzed using ImageJ Cell Counter plugin.  
2.6 Peripheral Injection of LPS 
In all studies using LPS, unless otherwise indicated, adult mice received a single (0.1 mg/kg, 
i.p) injection of either saline or LPS (from a 5 mg/mL stock). This dose of LPS was chosen 
because it is the minimum effective dose to elicit proinflammatory cytokine response and 
sickness behaviour in mice (Berg et al. 2004). In order to assess microglia morphology, mice 
were injected with 0.5 mg/kg i.p. LPS (0111:B4, 5 mg/mL), which is a dose previously used to 
study microglia dynamics (Hines et al. 2013) (Wohleb et al. 2012). 
2.7 ELISA 
Levels of IL-6 in plasma was determined using mouse IL-6 ELISA kit (ThermoFisher, 
cat#KMC0061). Plasma was defrosted on ice and diluted 4× with kit-supplied standard diluent 
buffer (SDB). ELISA procedure was performed according to manufacturer’s instructions. Data 
were obtained from 4 animals for each condition. Data was analyzed using Two-way ANOVA 
and sidak’s post hoc analysis.  
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2.8 RNA Extraction and qPCR 
Total RNA was extracted from the hippocampus and spleen using Aurum Total RNA mini-kit 
(Bio-Rad, cat#732-6870) and phenol/chloroform mix (Invitrogen, cat#15593-031). cDNA was 
synthesized from 2 µg of RNA using High Capacity cDNA RT kit (Applied Biosystems, 
cat#4368814). qPCR was performed in a CFX96 Real-time system (Bio-Rad) using SensiFAST 
SYBR NO-ROX kit (Invitrogen, cat#BIO-98020) and specific primer sets (shown below) for IL-
6, TNF-α, IL-1β, iNOS, COX-1, COX-2, BDNF, IL-1RA, IGF-1, and C1q, and RPL13a as the 
housekeeping gene. Data were analyzed using the comparative threshold cycle (Ct) method and 
results were expressed as fold difference from the control group identified (vehicle-saline or 
vehicle-LPS).  Data was analyzed using a student’s t-test. Specific oligonucleotide primers for 
qPCR are as follows: TNFα, forward, 5’- CTTCTGTCTACTGAACTTCGGG-3’, reverse, 5’- 
CAGGCTTGTCACTCGAATTTTG- 3’; IL-1β, forward, 5’- ACGGACCCCAAAAGATGAAG-
3’; IL-6, forward, 5’- GATGCTACCAAACTGGATATAATCAG-3’, reverse, 5’- 
CTCTGAAGGACTCTGGCTTTG-3’; iNOS, forward, 5’- AAGATGGCCTGGAGGAATGC-
3’, reverse, 5’- TGCTGTGCTACAGTTCCGAG-3’; BDNF, forward, 5’- 
TCTTTTCCGAGGTTCGGCTC-3’, reverse, 5’- CAGCCTACACCGCTAGGAAG-3’; COX-1, 
forward, 5’- CATTGCACATCCATCCACTCC-3’, reverse, 5’- 
ACAGGATTGACTGGTGAGGG-3’; COX-2, forward, 5’- GATGACTGCCCAACTCCC-3’, 
reverse, 5’- AACCCAGGTCCTCGCTTA-3’; C1Q, forward, 5’- 
CTTGGCAGTGTCCTGGTGAC-3’, reverse, 5’- CATGGTGTCCCTGCCTCC-3’; IGF1, 
forward, 5’- GGAGATGTACTGTGCCCCAC-3’, reverse, 5’- 
TAGGGACGGGGACTTCTGAG-3’; IL-1RA, forward, 5’- 
AACCAGCTCATTGCTGGGTACTTA, reverse, GCCCAAGAACACACTATGAAGGTC-3’; 
and RPL13a, forward, 5’- CTGCCCCACAAGACCAAGAG-3’, reverse, 5’- 
GGACCACCATCCGCTTTTTC-3’. 
2.9 Microglia Morphology Quantification  
Iba-1 was imaged using EVOS FL Auto 2 Imaging System (Thermo Fisher) and subsequently 
analyzed using ImageJ as previously described (Milior et al. 2016). Briefly, 4 representative 
images of the hippocampus of each animal were taken, of which 5 cells were chosen for analysis 
by an investigator blind to the treatment. Criteria for selection included the cells being entirely 
within the boundaries of the image and fully in focus. For each cell, the image was first set to 
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binary colour scheme, after which both the outermost points of each process, and also soma were 
traced around. The morphological index of the cell was determined as ratio of the soma area and 
the full arborisation. Twenty cells from each animal for each condition were analyzed and their 
averages were compared using GraphPad 7.0 (Prism) and Two-way analysis of variance 
(ANOVA), with sidak’s post hoc analysis.    
Figure 2.1 
 
 
 
Figure 2.3 Technique for microglia quantification using evos 
In order to investigate potential effects of CNO, LPS, or both, on microglia morphological 
dynamics, Iba-1 was imaged using EVOS FL Auto 2 Imaging System (Thermo Fisher) and 
analyzed using ImageJ. First, a representative image was taken from the Radiatum region of the 
hippocampus. Next, representative images were set to binary using Image J software (shown in 
1). (2) Individual representative cells that were entirely within image boundaries and in focus 
were chosen by an investigator blind to the treatment. (3) The soma of identified cells was traced 
with the free hand tool and measured. (4) The outermost extremeties of the cell’s processes were 
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traced around with the free hand drawing tool and measured. This was repeated for 5 cells, for 4 
different images per animal, yielding measurements for 20 different cells per animal.  
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2.10 Behaviour Experiments  
For all behavioural experiments, mice were injected with vehicle or CNO (1.0 mg/kg, i.p.; 3 
consecutive days) 30 minutes before their trial. All experiments were completed with male 
(Cx3cr1
CreER
-hM3Dq) mice during the light period (between 10:00 and 16:00 ). Mice were 3-6 
months old at the time of experiments. Prior to all behavioural tests, the mice were allowed to 
adapt to the test room for 30 min. All behaviour experiments are performed by investigators 
blind to the treatment. Littermate mice were randomly assigned for experimental groups. 
Behaviour experiments were completed in the following sequence: series one, open field (day 1), 
open field (day 2), social preference (day 3); series two, open field (day 1), open field (day 2), 
social memory (day 3); series three, light-dark box (day 1), elevated-plus maze (day 2), forced 
swim-test (day 3); series four, object recognition (day 3); series five, olfaction test (day 3). The 
same cohort of mice was used throughout a single series. A different cohort of mice was used for 
each different series.  
2.11.1 Social Preference  
Sociability was assessed as previously described (Kwon et al. 2006). Briefly, testing was done 
in a three-chambered apparatus (15×90×18.5 cm divided into three chambers of 15×29 cm and 
separated by dividers with a central 3.8×3.8 cm door) (shown in Figure 2.4) (Med Associates, St. 
Albans, VT, USA) that offers the subject a choice between a social stimulus and an object. To 
assess sociability, mice were first habituated for 10 min to the 3-chamber apparatus and two 
empty holed acrylic cups at each end (Leite et al. 2016). Mice were then locked in the center of 
the chamber for 5 min, during which a novel object (green lego block) was placed under the cup 
at one end, and a juvenile intruder of different background was placed under the cup at the other 
end. Time spent investigating the object and the intruder was recorded by an investigator blind to 
the treatment. Investigation was tracked when mice were sniffing a chamber within 5-cm radius 
(determined by Any-maze tracking software, Stoelting Co.). After the experiment, videos from 
each trial were re-watched and manually scored when mice sniffed through the holes of the 
chamber, by an investigator blind to the treatment. Performance is graphed according to the 
manual scoring, which on average differed by <3% compared to Any-maze tracking. In baseline 
experiments, data were analyzed using student’s t-test. In LPS experiments, data were analyzed 
using repeated measures Two-way ANOVA, and Sidak’s post hoc analysis.  
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Figure 2.2 
 
 
Figure 2.4 Social preference assay 
Shown is the three-chambered apparatus (15×90×18.5 cm divided into three chambers of 15×29 
cm and separated by dividers with a central 3.8×3.8 cm door) (Med Associates, St. Albans, VT, 
USA) where all social preference experiments were carried out. Briefly, animals were first 
habituated to the chamber for 10 minutes, with access to all chambers, including 1,2 and 3, with 
empty see through holed acrylic cups in chamber 2 and 3. Animals were then locked in chamber 
1 for 5 minutes while the chambers were filled with either a novel juvenile intruder (2) or a lego 
block (3). Time spent investigating chamber 2 and 3 within a 5-cm radius around the cups was 
recorded by an investigator blind to the treatment.     
1 
2 3 
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2.11.2 Social Memory 
Social memory was completed as previous described (Prado et al. 2006). Briefly, mice were 
singly housed 4 days prior to the experiment to establish territorial dominance. To test social 
interaction, a juvenile intruder was placed in the test subject’s home cage, under a transparent 
acrylic chamber allowing for olfactory investigation. Interaction was recorded as sniffing the 
cage within 5 cm (defined by Any-maze tracking software). Immediately before testing, mice 
were habituated to an empty acrylic chamber for 10 min; a juvenile intruder was then placed 
inside for a 5-min test period, followed by 3 consecutive trials with 15 min inter trial intervals. 
Prior to trial 5, to assess social memory, a new juvenile intruder was used. Time of investigation 
was manually recorded by an investigator blind to treatment. Time the mice spent sniffing the 
juvenile intruder during each of the 5 trials were compared using Repeated measures Two-Way 
ANOVA, and multiple comparisons test to compare trials.  
2.11.3 Open Field  
Open field activity was assessed as previously described (Janickova Helena et al. 2017; 
Martins-Silva et al. 2011) with small modifications. VersaMax Tracking System (X-Y and Z 
sensors) automatically recorded activity of mice in an open field box (40.64×40.64 cm
2
) 
(Omnitech Electronics Inc., Columbus, USA) divided into 4 equal quadrants separated by acrylic 
plexiglass, without an investigator present in the room. Two mice were placed in the lower left 
corner, of the bottom left box and top right box, respectively. The task was completed on two 
consecutive days with the exact same criteria. Locomotor activity is expressed as the total 
distance (cm) that mice travel during the trial, in comparison, time in center was recorded as the 
total time in seconds that mice spend within the inner (8×8 cm
2
) region of their box. All open 
field data (locomotor activity and time in center) are expressed as a sum of the first 60 min of the 
trial. For all open field experiments assessing baseline activity, a repeated measures two-way 
ANOVA, with sidak’s post hoc analysis was used. For all open field experiments assessing LPS-
induced neuroinflammatory behaviour, a student’s t-test was used.  
2.11.4 Light-Dark Box 
The following three behaviour experiments were performed by Sara Matovic of the Inoue 
Lab. The light-dark test was performed similar to previously described (A. M. Depino 2015; 
Amaicha Mara Depino, Tsetsenis, and Gross 2008). Mice were placed under the hole of the dark 
enclosure, and allowed to freely move for 5 minutes. Mice were automatically recorded with 
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VersaMax Tracking System (X-Y and Z sensors) in an open field box (40.64×40.64 cm
2
). A dark 
enclosure (Opto-Varimex-5 Light/Dark Box, 0150-LDB) was placed in the top half of the open 
field. Data are represented as total time the mice spend in the half without the dark enclosure. 
The crossover measurement – which records time in one region until the animals full body enters 
the other region - was used in order to prevent tracking of light side activity when the mice only 
have their head sticking out of the dark box Figure 2.7) Student’s t-test was used for analysis.  
2.11.5 Elevated Plus Maze  
To assess anxiety-like behaviour, the elevated plus maze was performed as previously 
described. Additional details are as follows, a maze with two open arms and two enclosed arms 
(open arms: 30×5 cm, surrounded by a 0.5-cm-high border; closed arms: 30×5 cm, surrounded 
by 19-cm-high walls; (Med Associates Inc., St Albans, USA) was used (Figure 2.8). Mice were 
placed on the central platform facing an open arm and were allowed to freely explore for 5 min. 
Any-maze tracking software (Stoelting Co.) recorded locomotor activity during the test. Total 
time mice spend in the open arms of the maze was compared using a Student’s t-test.  
2.11.6 Forced Swim Test 
Forced swim test was completed similarly to previously described procedure (Beraldo et al. 
2015) A plastic beaker (diameter, 15 cm; height, 25 cm) filled with 16 cm of water at 25 ℃ was 
placed in the center of a table underneath a camera with Any-maze software. Mice were placed 
in the bucket of water, and immobility/mobility was recorded for 6 min. The initial 2 min of the 
trial were discarded to account for the habituation phase. Data expressed as time of immobility 
during last 4 min was analyzed using Student’s t-test.  
2.11.7 Object Recognition  
In order to control for potential recognition deficits, a design similar to social memory was 
used (Prado et al. 2006). The time spent sniffing a holed acrylic chamber (within 5cm; defined 
by Any-maze software) was measured. Initially, a 10-min habituation phase was given where the 
mice explored an empty chamber in the test cage. For testing, a green rectangular shaped lego 
block was placed inside the chamber, and sniffing was measured during four consecutive 3-min 
trials with 10-min intervals. Prior to the 5
th
 trial, an unfamiliar object (a red prism lego block) 
was placed under the chamber. Results are graphed as time (seconds) the mice spent 
investigating the chamber during each trial, and analyzed using Two-Way ANOVA, and multiple 
comparisons test to compare trials. 
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2.11.8 Olfaction Test  
Olfaction was assessed as previously described (Prado et al. 2006). Briefly, to test olfactory 
deficits mice were exposed to the same scent (vanilla extract) for four consecutive 3-min trials 
with 10-min intertrial intervals. A 5×5 cm
2
 paper towel was soaked with 3 large drops of vanilla 
extract and placed in a small petri dish with several small holes in its cover to allow for olfaction 
but prevent physical interaction with the paper towel. The paper towel was replaced with a newly 
soaked one before each trial to maintain a consistent level of scent during each trial. Prior to trial 
5, the paper towel was instead soaked with caramel extract. Time of sniffing was manually 
recorded by an investigator blind to treatment. Time spent sniffing during each trial was 
compared using Two-way ANOVA and multiple comparisons test was used to compare trials. 
2.12 Statistical Analysis  
All statistical analyses were performed using GraphPad software (Prism). For two-group 
comparisons, Student’s unpaired t-test was used. For multiple group comparisons, two-way 
ANOVA was used with Sadik’s or Tukey’s post hoc test. Data are expressed as a mean +/- 
standard error of the mean (S.E.M.). 
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Chapter 3 
3. Results  
3.1 hM3Dq is expressed selectively in Iba1+ microglia in 
CX3CR1
CreER
-hM3Dq mouse brain 
We first characterized tamoxifen-inducible hM3Dq expression in microglia by using 
immunohistochemistry against HA (hM3Dq N-terminal tag) and the microglia marker Iba1. We 
found no background expression of HA in the absence of tamoxifen injection (Fig. 3.2.1A). In 
contrast to the more restricted expression in cultures, tamoxifen treatment caused widespread HA 
expression in mouse forebrain when examined at 10 day (Compare Fig. 3.2.1A and B) and 3 
months (Compare Fig. 3.2.1A and C) after tamoxifen administration. Indeed, because of the low 
turnover of microglia in the mouse brain (Füger et al. 2017), we detected significant labeling of 
h3MDq even after 12 months after tamoxifen treatment (not shown). To avoid expression of 
h3MDq in other myeloid-derived cells for our experimental manipulations, we waited 1 month 
after tamoxifen treatment of mice before performing experiments, so that populations of 
peripheral myeloid-derived cells could turn over, as previously described (Parkhurst et al. 
2013)(Fogg et al. 2006; van Furth and Cohn 1968). 
In order to determine the selectivity of h3MDq expression in vivo, we stained 
hippocampal brain sections with HA antibody and markers of microglia (Iba1, Fig. 2D), neurons 
(NeuN, Fig. 3.2.2E) or astrocytes GFAP (Fig 3.2.2F). These experiments demonstrated that 
hM3Dq is expressed mainly at the cell surface of microglia, with no co-localization with NeuN 
or GFAP. At 3 month after tamoxifen injection, 96.3% (n=696) of HA-positive cells were also 
positive for Iba-1, and 87.0% (n=770) of Iba-1 positive cells were HA-positive (Fig. 3.2.2G, 3 
different animals). We inspected other brain regions and also found widespread labeling of HA 
consistent with microglia morphology (not shown). These experiments together demonstrate that 
microglial hM3Dq is functional and expressed in most microglia in the brain, allowing the 
manipulation of Ca
2+
 signalling in vivo.  
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Figure 3.1.1 
 
Figure 3.1.1 Tamoxifen-inducible Cre-mediated expression of hM3Dq is specific to 
microglia. 
(A -C) Representative confocal images of hippocampus from Cx3cr1
CreER
-hM3Dq mice not 
treated with tamoxifen (A), and following 10 days (B) and 3 months (C) after tamoxifen 
injections. 
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Figure 3.1.2 
 
Figure 3.1.2 Tamoxifen-inducible Cre-mediated expression of hM3Dq is specific to 
microglia. 
The initial experiment and quantification (G) was performed by Muhammed Al-Onaizi, who also 
contributed representative images shown in F. (D-F) Representative confocal images showing 
distribution of hM3Dq marker HA (red) in tamoxifen-treated Cx3cr1
CreER
-hM3Dq mouse brain 
against (D) Iba1+ microglia (green), (E) NeuN+ neurons (green) and (F) GFAP+ astrocytes 
(green). Right panels show zoomed images of left panels with Hoechst nuclear stain (blue). (G) 
Quantification of cells double-labelled for Iba1 and HA (yellow), Iba1 alone (green), and HA 
alone (red).  
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3.2 Stimulation of Ca
2+
-signalling in microglia does not cause 
overt behavioural change, alterations in mRNA gene expression 
or synaptic transmission 
Recent studies suggest roles of microglia in modulating  a number of neuronal functions 
(Dissing-Olesen et al. 2014; K. Inoue et al. 2009; Milior et al. 2016) and behavior (Milior et al. 
2016) (Corona et al. 2010; Zhan et al. 2014) (Rogers et al. 2011). Thus, we first examined the 
behavioral consequences of activating hM3Dq in microglia of adult mice. We conducted a series 
of behavioral analyses over 3 days, where each day mice were treated with CNO (1.0 mg/kg, 
i.p.) or vehicle (0.5% DMSO in saline) 30 min prior to individual behavioral tests (Fig. 3.3.1A). 
Open field test conducted on two consecutive days (Day 1 and 2) to determine locomotor activity 
showed significant effects of Day on the total distance travelled (Fig. 3.3.1B), revealing expected 
habituation to the task on the 2
nd
 day (F(1,28)= 5.947, p= 0.0213). However, there was no effect of 
CNO (F(1,28)=3.066, p=0.9956) or interaction between CNO treatment and time (F(1,28)= 0.2367, 
p= 0.6304). Similarly, time in center (Fig. 3.3.1C) was affected by the day of the experiment, but 
not by CNO (time: F(1,28)=62.94, p<0.0001; CNO: F(1,28)=1.045, p = 0.3153; interaction: 
F(1,28)=1.031, p = 0.3187). These results suggest that activation of microglial hM3Dq did not 
affect locomotor activity, habituation to the task or anxiety-like behavior measured by time spent 
in the center of the box.  
On Day 3 we tested social behaviour using 3-chamber social preference task (Fig. 
3.3.1D). While the mice showed predicted preference to a conspecific over novel object 
(Vehicle; t-test (38)= 8.4444, p<0.0001; CNO; t-test (40)= 8.361, p<0.0001), CNO did not affect 
social interaction (t-test (39) = 0.9272, p=0.3595). Using a separate cohort of mice, we also 
examined social memory after 3 days of CNO or vehicle treatment (Fig. 3.3.1E). Both CNO and 
vehicle treated animals did not differ in interaction with the juvenile mice (F(1,28)=0.3988, 
p=0.5328). As expected, there was a significant effect of trial on time of interaction, suggesting 
mice remember the initial intruder (F(4,112)= 21.84, p<0.0001). These results suggested that 
activation of microglial Ca
2+
 signaling did not affect social behaviour. Using a third cohort of 
mice, we found that CNO did not affect anxiety-like behavior when tested using a light-dark box 
[Day 1, t-test(15)=0.1398, p=0.8907; (Fig. 3.3.1F)] and elevated plus maze [Day 2, t-
test(15)=0.007498, p=0.9941; (Fig. 3.3.1G)]. We also did not detect any effect of CNO in 
depression-like behavior using the forced swim test [Day 3, t-test(15)=0.4787, p=0.6391; (Fig. 
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3.3.1H)]. As a control experiment, we injected mice for 3 consecutive days then assessed 
olfactory memory (Fig. 3.3.1I) and object memory (Fig. 3.3.1J). Similar to our social memory 
results, we found that there was a significant effect of trial on time of smelling (F(4,56)=24.25, 
p<0.0001) and object investigation (F(4,52)=19.74, p<0.0001), but there were no effect of CNO or 
interaction in olfaction (CNO: F(1,14)=0.004324, p=0.9485; interaction: F(4,56)=1.156, p=0.3403), 
or object recognition (CNO: F(1,13)=0.1905, p=0.6697; interaction: F(4,52)= 0.8272, p=0.5139). 
Together, these experiments suggest that activation of Ca
2+
 signalling in microglia does not 
cause any sort of sickness behavior nor does it affect performance in a number of behavioral 
tasks that can be modified by neuroinflammation. 
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Figure 3.2.1 
 
 
 
 
Figure 3.2.1 Behaviour during noninflammatory conditions 
Experiments shown in figures F, G, and H were performed by Sara Matovic.  
(A) Design of study to investigate behaviour and neurochemical responses of Cx3cr1
CreER
-
hM3Dq mice under baseline noninflammatory conditions. CNO or vehicle (0.5% DMSO) (1.0 
 
40 
 
mg/kg) was injected 30 minutes before each behavioural task. (B) B-C) Total distance travelled 
and time spent in the center in open field assessment on two consecutive days. D) Time spent 
investigating a caged juvenile in 3-chamber social preference task. E) Time spent interacting 
with a caged intruder in home cage. A new intruder is introduced in trial 5. 1 trial = 5 mins. F) 
Time spent in light side of light-dark box (LDB). G) Time spent in the open arm of an elevated 
plus maze. H) Total time of immobility in forced swim test (FST). Data represents 2-6 min. I) 
Time spent sniffing enclosed vanilla scent. A new scent (caramel) was introduced for trial 5. J) 
Time spent investigating a novel object. A new object was introduced for trial 5. All data was 
analyzed using two-way ANOVA or student’s t-test. For two-way ANOVA, sidak’s post hoc 
analysis was used.  
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Previous literature supports a role of microglia Ca
2+
 signalling in modulation of 
neuroinflammation and cytokine expression in the brain (Hoffmann et al. 2003; Tvrdik and 
Kalani 2017). Therefore, in order to determine the effect of microglia Ca
2+
 signalling on gene 
expression in the brain, with a new cohort of mice we used qPCR measurement to analyze 
expression of cytokines and select genes in the hippocampus of mice 2 hours after the fourth 
consecutive CNO (1 mg/kg) treatment (Day 4-shown in Fig. 3.3.2K-U). As a start, we focused 
on hippocampus as accumulating data indicate the importance of hippocampus in social memory 
(Okuyama 2018)which is affected during inflammation/sickness behavior (Czapski, Gajkowska, 
and Strosznajder 2010). However, we did collect tissue samples from other brain areas including 
the prefrontal cortex, amygdala and hypothalamus: these samples will be analyzed in the future. 
Interestingly, cytokines have been implicated in neural plasticity in the hippocampus. For 
example, low levels of proinflammatory cytokines expression appears to be necessary for LTP 
induction in non-inflammatory condition (McCusker and Kelley 2013) whereas high levels of 
proinflammatory cytokines can impair memory (Rogers et al. 2011).  
hM3Dq induced microglia Ca
2+
 signalling did not alter mRNA expression of classic 
proinflammatory cytokines TNFα, IL-6, or IL-1β (Fig. 3.3.2K-M). Nor did it alter gene 
expression of other target genes, including iNOS, COX-1, COX-2, BDNF, or IL-1RA (Fig. 
3.3.2N-R). There was also no effect of microglia Ca2+ signalling on mRNA expression of C1Q, 
or IGF1 (not shown). In a control experiment, we found no effect of CNO on mRNA expression 
of TNFα, IL-6, or IL-1β in the spleen of this same cohort of mice (Fig. 3.3.2S-U). 
We next examined the effects of microglial hM3Dq activation on synaptic transmission using 
whole-cell patch clamp electrophysiology in brain slices prepared from Cx3cr1
CreER
-hM3Dq 
mice. Acute CNO treatment of brain slices did not change either the frequency (t-test(10)=0.5452, 
p=0.5976) or amplitude (t-test(10)=0.758, p=0.4659) of mEPSCs recorded from CA1 pyramidal 
neurons (Fig. 3.3.2T,U). In conclusion, hM3Dq induced microglia Ca
2+
 signalling did not induce 
any overt sickness behaviour in mice, neuroinflammatory gene alteration, nor did it trigger 
changes to synaptic transmission in brain slices.  
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Figure 3.2.2 
 
    
  
 
43 
 
Figure 3.2.2 mRNA gene expression and synaptic transmission under noninflammatory 
conditions 
Experiments shown in figures S and T were performed by Sara Matovic of the Inoue lab. (Fig.K-
R) qPCR measurements of mRNA expression of select genes in the hippocampus 2 hr after CNO 
or vehicle: TNFα (p=0.223), IL-6 (p=0.376), IL-1β (p=0.256), iNOS (p=0.213), COX-1 
(p=0.894), COX-2 (p=0.176), BDNF (p=0.253), IL-1RA (p=0.980). (Fig. S-U) qPCR 
measurements of mRNA expression of select genes in the spleen 2 hr after CNO or vehicle: 
TNFα (p=0.577), IL-6 (p=0.197), IL-1β (p=0.117). (V,W) Single-cell patch clamp recordings of 
IE (ms) (V) and sEPSC amplitude (W) in Vehicle and CNO treated Cx3cr1
CreER
-hM3Dq cells. 
All data shown are tamoxifen injected Cx3cr1
CreER
-hM3Dq mice. Data are represented as mean 
+/- SEM, and analyzed using student’s t-test. The same mice were used for analysis of 
hippocampus and spleen tissue. Reduced n values from the spleen are a result of technical failure 
during RNA extraction.   
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3.3 Stimulation of Ca
2+
-signalling in microglia attenuates LPS-
induced sickness-like behaviour and upregulation of 
proinflammatory cytokines in the brain  
The results described above collectively showed that, under physiological conditions, 
activating microglial hM3Dq Ca
2+
 signalling causes no overt changes in sickness-related 
behaviors. During inflammation, on the other hand, microglia has long been thought to play roles 
in sickness behavior as cellular intermediates that respond to inflammatory stimuli and signal to 
neurons (Robert Dantzer et al. 2000; Konsman, Parnet, and Dantzer 2002). Thus, we next tested 
whether microglial Ca
2+
 activation would modulate mouse behavior following systemic LPS 
administration (100 μg/kg, i.p.), a model of systemic inflammation that drives sickness behavior 
(Berg et al. 2004). 
We initially stimulated microglia hM3Dq with CNO (1 mg/kg) for 4 consecutive days 
and then challenged mice with LPS on day 4, prior to behavioural assays during expected time of 
sickness (Fig. 3.4.1A). The animals decreased their body weight following LPS treatment (Fig. 
3.4.1B; effect of Day: F(2,40)=59.64, p<0.0001), suggesting LPS triggered the previously reported 
anorexic response (Robert Dantzer et al. 2008). However, weight loss was not affected by CNO 
(F(1,20)=0.02686, p=0.8715) nor there was interaction between day and treatment (F(2,40)=1.098, 
p= 0.3434). Social withdrawal is characteristic of sickness behaviour, so we repeated social 
preference test 2 h or 24 h after LPS treatment. We selected these time points based on previous 
study showing that social withdrawal is most prominent within the first 12 h after LPS (Corona 
et al. 2010) and normal social interaction is restored 24 h after LPS injection.  
Control mice showed reduced interaction with the social stimulus at 2 h, but investigation 
times returned to baseline levels observed prior to LPS treatment at 24 h (Fig. 3.4.1C). 
Interestingly, mice treated with CNO (1 mg/kg) did not present social withdrawal at 2 after LPS 
treatment (Fig. 3.4.1C). There was a significant effect of CNO on social investigation 
(F(1,20)=8.946, p=0.0072) and of time after LPS injection (F(1,20)=5.469, p= 0.0299), but there was 
no interaction (F(1,20)=1.318, p= 0.2646). CNO-treated mice spend significantly longer time in 
social interaction than vehicle mice when examined at 2 h (p=0.0093), but not at 24 h (p=0.2737) 
after LPS injection. These results indicate that the activation of microglial hM3Dq signaling 
attenuated LPS-induced reduction of social interaction. After completion of social preference, 
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the same cohort of animals were immediately assessed in open field (shown in 24 h time point). 
This time point was chosen based on previous research suggesting the peak LPS-induced 
hypoactivity does not occur until 24 h after treatment (Corona et al. 2010). We found that CNO 
attenuated LPS-induced hypoactivity (Fig. 3.4.1D; t-test(20)= 2.107, p=0.0479). There was a trend 
in favour of CNO-treated animals spending more time in the center compared to vehicle-treated 
animals, however this was not significant (Fig. 3.4.1E; t-test(20)= 2.06, p=0.0527). Overall, 
activation of hM3Dq signalling in microglia attenuated some, but not all symptoms of sickness 
behavior.  
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Figure 3.3.1 
 
Figure 3.3.1 Microglial hM3Dq activation by CNO alleviated LPS-induced sickness 
behaviour  
A) Design of study to investigate behaviour of Cx3cr1
CreER
-hM3Dq mice following LPS (0.1 
mg/kg i.p.). B) Body weight following LPS for all animals in experiment shown. (n=11, per 
treatment). C) Total time spent investigating a caged juvenile intruder in a 3-chamber apparatus. 
Behaviour 2h and 24h after acute LPS injection shown. D,E) Locomotor activity (D) and total 
time spent in center (E) in an open field assessment 24 hr after LPS (completed immediately 
following 3-chamber social preference task). All data are represented as mean +/- SEM, * 
p<0.05, ** p<0.005, means are significantly different from each other. All data was analyzed 
using two-way ANOVA with sidak’s post hoc, or student’s t-test.  
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 Microglia may contribute to sickness behaviour by stimulating de novo expression of 
inflammatory genes in the brain (Konsman, Parnet, and Dantzer 2002) (Biesmans et al. 2015; 
Karman et al. 2006; Matyszak 1998; Skelly et al. 2013). Thus, we hypothesized that the 
attenuattion of LPS-induced sickness behaviour by microglial hM3Dq activation could be 
paralleled by changes in inflammatory gene expression. To test this, we examined mRNA levels 
of various inflammatory genes in the hippocampus using qPCR in CNO and vehicle-treated mice 
at 2 h after LPS or saline injection (Fig. 3.4.2F). Pre-treatment with CNO significantly attenuated 
LPS-induced gene expression of TNFα (t-test, p=0.0061, Fig 3.4.2G), IL-6 (t-test, p=0.0200), 
and IL-1β (t-test, p= 0.0121, Fig 3.4.2I). In contrast, CNO-treated animals did not show altered 
expression of other inflammatory-related genes, including iNOS (Fig. 3.4.2J: p=0.6884), COX-1 
(Fig. 3.4.2K: p=0.8589), COX-2 (Fig. 3.4.2L: p=0.1978), BDNF (Fig. 3.4.2M: p=0.7615), or IL-
1RA (Fig. 3.4.2N: p=0.1933). C1Q and IGF1 mRNA expression was also not altered by CNO 
after LPS treatment (data not shown). These qPCR data suggests that CNO triggered a Ca
2+
 
dependent selective anti-inflammatory effect, as not all genes were affected.  
We also examined mRNA expression of TNFα, IL-6, and IL-1β in the spleen (Fig 3.4.2O-Q), 
a major reservoir of peripheral monocytes (Swirski et al. 2009), collected from the same mice 
examined for brain inflammatory responses. We found that CNO did not alter LPS-induced 
levels of IL-6 (p=0.1090) or IL-1β (p=0.1480). However, CNO did significantly attenuate LPS-
induced expression of TNFα mRNA in the spleen (p=0.0181). As an additional readout for 
peripheral inflammatory response, we also analyzed levels of IL-6 in plasma in response to LPS, 
using ELISA (Fig. 3.4.2R). IL-6 levels in peripheral circulation were not altered by CNO (t-test, 
p=0.1781). In the absence of LPS, average levels of IL-6 were near the threshold of detection for 
both vehicle (17.808 pg/ml) and CNO treated mice (33.592 pg/ml). These results suggest that 
microglia Ca
2+
 signalling affects mainly the synthesis of cytokines in the brain after LPS 
injection, with exception of TNF.  
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Figure 3.3.2 
 
   
 
Figure 3.3.2 Microglial hM3Dq activation by CNO alleviated LPS-induced 
neuroinflammation  
F) Design of study to investigate gene expression in hippocampus/spleen of tamoxifen treated 
Cx3cr1
CreER
-hM3Dq mice after LPS. G-L) qPCR measurements of mRNA expression of select 
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genes in the hippocampus 2 hr after LPS: TNFα (p=0.006), IL-6 (p=0.020), IL-1β (p=0.012), 
iNOS (p=0.690), COX-1 (p=0.859), COX-2 (p=0.198), BDNF (p=0.762), IL-1RA (p=0.193). R) 
ELISA measurement showing plasma IL-6 levels 2 h after LPS. O-Q) qPCR measurements of 
mRNA expression of cytokines in the spleen 2 hr after LPS: TNFα (0.043), IL-6 (0.130), IL-1β 
(0.101). All data are represented as mean +/- SEM. All data was analyzed using student’s t-test, 
p<0.05, **= p<0.005. Hippocampus, spleen, and plasma data are from the same mice. Reduced 
n values (spleen data) are a result of technical failure during RNA extraction.  
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3.4 CNO does not affect LPS-induced neuroinflammatory 
response in the hippocampus of wildtype mice  
While CNO is believed to specifically act on DREADDs, few studies have reported non-
specific effects of CNO and/or its metabolites clozapine and N-desmethylclozapine (Gomez et 
al. 2017; MacLaren et al. 2016; Manvich et al. 2018). To test whether the effect of CNO we 
observed in cytokines depended on DREADD expression, we repeated the LPS x CNO 
experiments in control mice and examined cytokine mRNA levels in the hippocampus 2 hr after 
LPS (0.1 mg/kg, i.p.) injection (Fig. 3.5A). We detected significant effects of LPS in 
upregulating mRNA for IL-1β (Fig. 3.5B; F(1,24)=12.33, p=0.0018), IL-6 (Fig. 3.5C; F(1,24)=6.15, 
p=0.0205), and TNFα (Fig. 3.5D; F(1,24)=11.3, p=0.0026). In these control mice CNO had no 
effect on LPS-induced mRNA expression (IL-1β: F(1,24)=0.1825, p=0.6730; IL-6: F(1,24)= 0.027, 
p=0.8686; TNFα: F(1,24)= 0.2964, p=0.5912). These results support the interpretation that CNO 
does not affect LPS-induced cytokine synthesis in the absence of hM3Dq expression. Moreover, 
control experiments using 1 mg/kg of CNO did not reveal any effects on behavior tests in mice 
not expressing DREADDs (not shown), consistently with the lack of changes in behavioral 
parameters in the absence of LPS injection.  
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Figure 3.4 
 
 
 
Figure 3.4 CNO did not alter cytokine expression in hippocampus of wildtype mice 
A) Design of study to investigate mRNA expression in hippocampus of wildtype mice. B-D) 
qPCR measurement of mRNA expression of IL-1b, IL-6, and TNF-α in hippocampus of wildtype 
mice 2 hr after LPS. Data are represented as mean +/- SEM, and analyzed using two-way 
ANOVA with sidak’s post hoc analysis.  
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3.5 CNO or LPS did not alter microglia morphology 
Morphology of microglia is widely used as a marker for activity changes of microglia 
(Madore et al. 2013), including after systemic LPS injection (Hines et al. 2013, 4).  To gain 
further insight how CNO altered LPS-induced microglia activation, we examined the changes in 
microglial morphology using immunohistochemistry for Iba-1, a microglia/macrophage-specific 
calcium-binding protein commonly used to label microglia (Madore et al. 2013). As illustrated in 
Fig 3.4.1A, a cohort of mice used for the behavioral study after LPS/CNO injections were further 
challenged with a higher dose of LPS (500 µg/kg, i.p.) with or without pre-treatment of CNO and 
sacrificed 48hr later for histology. We found that CNO, LPS, or the combination of both had no 
effect on microglia area of process coverage (arborisation) (Fig. 3.6C, F=(3,11)=0.776, p= 0.531) 
or soma size (Fig. 3.6D, F= (3,11)=0.584, p= 0.640) compared to baseline microglia. The 
morphological index was also similar between treatment groups (Fig. 3.6E, F=(3,11), p= 0.995). 
These data suggest that LPS, at the dose used in this study, did not initiate detectable 
morphology changes in microglia in the CA1, and CNO alone or in combination with LPS did 
not alter microglia morphology.  
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Figure 3.5 
 
 
 
Figure 3.5 CNO or LPS did not alter microglia morphology  
A) Timeline of study to investigate microglia morphology following CNO and/or LPS. Note 1
st
 
LPS injection is (0.1 mg/kg), 2
nd
 LPS injection is (0.5 mg/kg). B) Representative Evos images 
from hippocampus of tamoxifen treated Cx3cr1
CreER
-hM3Dq mice following treatment of 
Vehicle/LPS or CNO/LPS. C-E) Quantification of total microglia process coverage 
(arborisation), cell body size (soma), and ratio between arborisation and soma (morphological 
index) using image J software. Data are represented as mean +/- SEM. Note each dot = avg. of 
20 cells. All mice represented completed behaviour series one before subsequent LPS injection 
on day 7 (see timeline).  
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Chapter 4 
4. Discussion  
Microglia sense exogenous and endogenous inflammatory signals, and orchestrate 
subsequent neuroinflammation that is central to sickness behaviour. Accumulating evidence 
indicate that the reactivity of microglia to inflammatory stimuli is labile, influenced by the 
history of their previous activities and the current status of the brain. Sensitization may underlie 
vulnerability to subsequent insults (Niraula, Sheridan, and Godbout 2017). The key finding of 
this project was that chronic activation of hM3Dq- signalling in microglia attenuates microglial 
reactivity to LPS-induced systemic inflammation, alleviating the production of proinflammatory 
cytokines in the brain and ensuing sickness behaviour. 
4.1 CX3CR1CreER mice to genetically manipulate microglia 
To study the consequence of Gq-type GPCR signaling in microglia in vivo, we generated 
CX3CR1
CreER
 -hM3Dq mice,  microglia/monocyte specific promoter CX3CR1 drives the 
expression of hM3Dq expression in a tamoxifen-inducible and Cre-dependent manner (Parkhurst 
et al. 2013). CX3CR1 + monocytes rapidly turnover (0.1 %/hour) from a CX3CR1 - bone marrow 
precursor population and exhibit near complete turnover after 30 days (Fogg et al. 2006), 
whereas the turnover of CX3CR1+ microglia is substantially slow (0.2%/day in the 
hippocampus, 0.075% in the cortex)(Tay et al. 2017) Thus > 1 month after tamoxifen injection, 
hM3Dq is expected to be present only in microglia.  
We found that 96.3% of Iba1 cells were labelled by HA-tagged hM3Gq, and 87% of HA cells 
were Iba-1 positive. This is comparable with previous use of CX3CR1
CreER
 mice to genetically 
manipulate microglia, which showed (98.8% +/- 1.3%) co localization of CreER-dependent 
expression of EYFP and microglia marker Iba1 (Parkhurst et al. 2013). In line with the low 
turnover rate of microglia (Lawson, Perry, and Gordon 1992), the expression of HA epitope tag 
was strong from 3 months up to 1 year after tamoxifen injection. It should be noted that 
microglia turnover rate is higher in the olfactory bulb, hippocampus, and cerebellum, compared 
to cortex, midbrain, and hypothalamus (Tay et al. 2017). However, even the most rapid turnover 
rates (8 months in the olfactory bulb and 15 months in the hippocampus) are well beyond our 3 
month time period post tamoxifen.  
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Microglia proliferation is maintained by coupled proliferation of resident microglia rather 
than infiltration of bone-marrow-derived immune cells (Askew et al. 2017). That being said, it 
should be noted that during pathological conditions like traumatic brain injury and ischemic 
brain injury, Alzheimer’s disease, prion disease, and multiple sclerosis, the BBB often becomes 
compromised and infiltration of bone marrow-derived immune cells becomes common (Gomez-
Nicola and Perry 2015; Brown and Neher 2014; Hanisch and Kettenmann 2007). Thus, studies 
attempting to characterize microglia-DREADD dynamics in pathological conditions must take 
this into consideration. Indeed, microglia dynamics have recently been elegantly investigated by 
Tay and colleagues, who employed a multicolor fluorescence fate mapping system allowing for 
identification of specific mechanisms of turnover rates, which differ by brain region and 
subpopulations of microglia (Tay et al. 2017). This too also acknowledges the necessity to 
account for differences in steady state and disease. In this project, we do not consider BBB 
integrity to be an issue, since the low dose of LPS (100 μg/kg) we used does not compromise the 
BBB integrity (Banks and Robinson 2010; Salam, Pariante, and Zunszain 2017).  
4.2 Microglia Gq signalling in healthy conditions 
By using the above described strategy to express hM3Dq in microglia, we found that a 
sub-chronic stimulation of microglial hM3Dq signalling with systemic injections of CNO for 3 
consecutive days did not elicit any detectable behavioral changes, including social behaviour, 
locomotor activity, anxiety and stress-related behaviour, or recognition and olfaction, that are 
relevant to sickness behavior (Robert Dantzer and Kelley 2007; Skelly et al. 2013). In line with 
the lack of behavioral change, we also did not detect significant changes in the mRNA levels of 
cytokines (IL-1β, IL-6, TNFα) and other inflammatory genes (COX-1, COX-2, iNOS, BDNF, 
IL-1RA) and genes not shown (C1Q, IGF-1) in the brain after 3 daily CNO injections. Taken 
together, we concluded that the activation of microglial hM3Dq signalling does not cause 
classical neuroinflammatory response.  
While microglial hM3Dq stimulation did not cause neuroinflammation, it is still possible 
that other aspects of microglial function maybe affected that were not detected by our array. Gq 
signaling resulting from hM3Dq activation leads to an elevation of intracellular calcium as 
predicted from canonical Gq signaling as well as confirmed by our own in vitro assay. It has 
been shown that Cx3Cr1 receptor signaling, which also elevates intracellular Ca
2+
 levels, 
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contributes to modulation of AMPA receptor function at active glutamatergic synapses 
(Ragozzino et al. 2006). Similarly, dysregulation of fraktalkine signalling decreases hippocampal 
neurogenesis (Bachstetter et al. 2011), and also alter synaptic plasticity mechanisms (e.g. LTP 
and LTD) (Bertollini et al. 2006). Related to this, it is worth noting that cytokines, such as IL-1β, 
are expressed at low levels under physiological conditions and are believed to contribute to 
synaptic plasticity, learning and memory (Raz Yirmiya and Goshen 2011). Pharmacological 
blockade of IL-1 receptor has been shown to impair hippocampal-dependent learning tasks (R. 
Yirmiya, Winocur, and Goshen 2002). Further studies are required to understand potential 
consequences of microglial hM3Dq-signaling under physiological conditions.  
A recent study showed that the activation of hM3Dq expressed in spinal microglia under 
CD68 (microglia/macrophage) promoter induced allodynia, which was abolished by intrathecal 
administration of IL-1 receptor antagonist in rats (Grace et al 2018). Along the same line, BV2 
cells (microglia cell line) stably expressing hM3Dq respond to CNO with an upregulation of 
inflammatory cytokines including IL-1β (Grace et al 2018). This pro-inflammatory consequence 
of hM3Dq signaling in certain types of microglia is not in line with our results. However, 
important differences between this and our studies is the promotor used to drive hM3Dq 
expression. CD68 promoter used by Grace et al (2018) to drive Cre expression drives Cre not 
only in microglia by also by perivascular and meningeal macrophages in the brain, and its 
expression is upregulated by inflammatory stimuli such as LPS (Papageorgiou et al. 2016, 4) 
whereas the CX3CR1 promotor is specific to microglia in the brain). It is therefore possible that 
hM3Dq is expressed in different populations of cells in the two studies providing a plausible 
explanation for the different consequences of hM3Dq signaling. Furthermore, our observation of 
CX3CR1CreER-hM3Dq mice during injection protocols and behavioural experiments suggests 
mice did not experience discomfort. We did not detect any changes in baseline behaviour in 
CNO treated animals, and no abnormalities during open field or social interaction were detected, 
which is an indicator of pain (Kolstad et al. 2012). Moreover, Grace et al. used adeno-associated 
virus and drove hM3Dq expression under CD68 promotor activity in rats. Caution is warranted 
when generalizing molecular and functional responses of microglia between species (rat versus 
mice). For instance, network differences in chemokine and cytokine expression in mice 
compared to rat brain have been identified following oxygen-glucose deprivation (Du et al. 
2017). Furthermore, microglia markers including Iba1, CD11b, and CD68 differ between species 
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during activation states (Lam, Lively, and Schlichter 2017). This makes it an important 
consideration since both the referenced study and the present study used LPS to provoke 
inflammation.  
The use of adeno-associated virus is another important difference, since microglia are 
immune cells and are known to respond to viral infection (Sakurai et al. 2008). Our mouse model 
drives hM3Dq expression under CAG promoter (following Cre-dependent removal of floxed-
STOP cassette), resulting in stable hM3Dq expression that is insensitive to inflammatory 
signaling. For these reasons, we speculate that the differences between these two studies are due 
to difference in the population of cells that express hM3Dq.  
4.3 LPS-induced sickness behaviour 
In contrast to stimulation of microglia hM3Dq under physiological conditions, 
stimulation of microglia hM3Dq for 4 consecutive days prior to LPS-challenge attenuated the 
development of sickness behavior as evidenced by the amelioration of social withdraw and 
decrease in open field locomotor activity. The attenutation of sickness behavior was paralleled 
by the decrease of LPS-induced upregulation of brain cytokine levels including IL-1β, IL-6 and 
TNFα, indicating that sub-chronic activation of microglial hM3Dq signaling prior to LPS-
induced systemic inflammation altered neuroinflammatory response.  
Of interest is the finding that this priming effect is rather specific to certain aspects of 
neuroinflammatory response, because CNO treated mice still showed an intact anorexic response 
(body weight loss) to LPS. Similarly, LPS-induced upregulation of COX-2 and mPGES-1, two 
key enzymes necessary for PGE2 synthesis, were not affected by CNO treatment. Together, 
these findings are in line with previous findings that administration of COX-2 inhibitors blocks 
the anorexic response in LPS-treated mice and rats (Johnson et al. 2013; Pecchi et al. 2009; Jin et 
al. 2016), and that COX-2 KO mice are resistant to LPS-induced anorexia (Nilsson et al. 2017). 
Conversely, inflammation-induced hypoactivity persists in mice with selective deletion of COX-
2 and mPGES1 in brain endothelial cells, but these mice lack typical fever response (Wilhelms et 
al. 2014). One potential explanation for the lack of effect on COX-2 mediated anorexia is 
microglia express little or no COX-2 after immune challenge (Engström et al. 2012). Meanwhile, 
other cell types are involved in COX-2 production during LPS-induced systemic inflammation 
(via synthesis of PGE2), including neurons, astrocytes, and endothelial cells (Shiow et al. 2017, 
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2017). While the precise contribution of each cell type, including microglia, to anorexia remains 
to be identified (Nilsson et al. 2017), this particular finding provides clues as to the specific 
mechanisms behind the characteristic wasting of body weight. Indeed, based on this negative 
finding, we would also not expect to see an effect of microglia hM3Dq-signalling on fever, 
cortisol release, hyperalgesia, or lethargy, since these LPS-stimulated inflammatory responses 
are also regulated by prostaglandin/COX signalling. These data suggest that microglial hM3Dq 
signaling, or microglia-dependent inflammatory response, contribute to some but not all aspects 
of sickness behavior.  
Future studies are warranted to dissect out specific inflammatory and downstream neural 
mechanisms contributing to specific aspects of sickness behavior. For instance, whether 
microglia hM3Dq signalling modulates LPS-induced depressive behaviour awaits future study. 
There is evidence of a dissociation between sickness and depressive-like behaviours triggered by 
systemic inflammation. Depressive-like behaviour, indicated by increased time of immobility in 
forced swim tests (FST) and tail-suspension tests (TST), remain after food intake and locomotor 
activity have returned to baseline (O’Connor et al. 2009)(Salazar et al. 2012; Dinel et al. 2014). 
It is speculated that depression develops in response to immune challenge once the initial 
sickness response has been prolonged (Robert Dantzer et al. 2011; Liu et al. 2013; Moreau et al. 
2008). The kynurenine pathway is likely to play an important role in LPS-induced depressive 
behaviour, LPS-induced cytokines activates the kynurenine rate-limiting enzyme indoleamine 
2,3-dioxygenase (IDO), which parallels development of depressive-like behaviour (Moreau et al. 
2008) (Salazar et al. 2012; Dinel et al. 2014; O’Connor et al. 2009; Fu et al. 2010; Liu et al. 
2013; Meier et al. 2016). Since IDO activity is focused in activated monocytes and microglia 
(Moroni et al. 1991) our microglia-DREADD mouse is a promising tool to investigate LPS-
induced depressive behaviour in future studies.  
4.4 Inflammatory Cytokines, and Microglia priming 
Sickness behavior is at least in part dependent on microglia and brain cytokines (Henry et 
al. 2008). TNFα and IL-1β are necessary for sickness behaviour, while IL-6 is required for the 
febrile response to LPS (Robert Dantzer et al. 2008). Indeed, it is predicted that TNFα, IL-1β, 
and IL-6 alter behaviour by direct actions on neurons (Poon et al. 2015). Microglia are primary 
producers of proinflammatory cytokines, and inhibiting their inflammatory responses with 
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minocycline abolishes sickness behaviour and cytokine response to LPS (Henry et al. 2008). 
Accordingly, we report a substantial attenuation of microglial-regulated cytokine synthesis by 
subchronic activation of hM3Dq signaling. We found that the LPS-induced increase in mRNA 
for TNFα, IL-6, and IL-1β was attenuated in CNO treated animals. The difference in CNO 
effects in healthy vs. inflammatory conditions points to the importance of understanding 
modulatory, rather than stimulatory, effects of hM3Dq signalling. For example, it has been 
shown that pharmacological activation of metabotropic glutamate receptor 5, Gq-type GPCR, 
reduced microglia activation in response to LPS, marked by reduced ROS, nitric oxide, and 
TNFα production in primary microgial culture (Byrnes et al. 2009).  
The modulation of microglial functions, such as their sensitivity to inflammatory 
response, is an important topic with relevance to aging, neurodegeneration and traumatic brain 
injury (TBI). There is clear evidence of elevated baseline brain inflammation with age in both 
rodents and humans, where microglia likely play important roles (Fenn et al. 2013; J. P. Godbout 
et al. 2005; Henry et al. 2009). In the context of systemic inflammation, intraperitoneal (i.p.) 
administration of LPS triggers a prolonged and exaggerated neuroinflammatory response in aged 
mice compared to young adult controls (Wynne et al. 2010). Importantly, the elevation of 
cytokines is unique to the brain, and not present in plasma in aged animals (Barrientos et al. 
2006), suggesting priming likely occur at the level of the brain. In line with this idea, microglia 
in the aged brain show elevated levels of inflammatory markers, such as MHC II, and produce 
higher levels of IL-1β in response to inflammatory stimuli (Henry et al. 2009).  
Animal models of neurodegeneration, particularly prion disease and AD, also show 
markers of microglia priming including elevated MHC ll and CD68 expression (Cameron and 
Landreth 2010; Cunningham et al. 2005). Mice models of presymptomatic prion disease 
displayed heightened inflammatory response and neuronal death to i.c. and i.p. LPS, compared to 
non-prion controls (Cunningham et al. 2005). Systemic LPS caused significant increase in IL-1β 
in transgenic AD mice compared to non-transgenic controls, and this significantly contributed to 
pathology (Krstic et al. 2012; Sly et al. 2001). Indeed, a recent study suggests microglia use 
epigenetic mechanisms that reprogram their responses to neurodegeneration and inflammation. 
Pathological and inflammatory responses to onset of Aβ deposition or stroke pathology were 
exacerbated in animals that were previously exposed to acute LPS injection (Wendeln et al. 
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2018). This immune training effect was inhibited when Tak1 or Hdac1/2 were knocked out, two 
primary genes responsible for epigenetic mechanisms in microglia network (Datta et al. 2018; 
Goldmann et al. 2013). In contrast, consecutive doses of LPS (4X) induced a tolerance effect, 
whereby the inflammatory response to Aβ deposition or stroke pathology is attenuated (Wendeln 
et al. 2018), similarly to our study. Indeed, other studies support the possibility of an alternative 
tolerance effect to consecutive doses of LPS (Norden et al. 2016; Fukushima et al. 2015). The 
differential mechanisms behind these opposing responses is unclear.  
The literature on microglia priming suggests that the modulation of their reactivity to 
inflammatory stimuli is not unique to specific pathologies. Rather, microglia priming is affected 
by any brain tissue injury which triggers an inflammatory cascade, suggesting it is cytokines and 
the molecular signals of inflammation that prime microglia. Accordingly, the spectrum of stimuli 
that invokes microglia priming is extended to traumatic brain injury, which  triggers prolonged 
microglia activation in animal studies (Loane et al. 2014; Ziebell et al. 2012). This prolonged 
activation further sensitizes microglia for subsequent inflammatory stimuli. Indeed, repeated 
blows to the head may also sensitize microglia to inflammation; the initial blow provides the 
priming, while subsequent blows lead to elevated inflammatory responses (Weil, Gaier, and 
Karelina 2014). Both astrocytes and microglia presented an inflammatory phenotype up to at 
least 12 months after repeated blows, compared to 6 months after a single TBI (Mouzon et al. 
2014). Indeed, numerous and consecutive head traumas has been linked to the neurodegenerative 
disease chronic traumatic encephalopathy (CTE) (Petraglia et al. 2014).  
Microglia reactivity may also have relevance for neuropsychiatric disorders. For instance, 
there is evidence of depressive like disturbances following systemic immune challenge, which 
are more pronounced in aged compared to young adult control mice (Corona et al. 2010; 
Jonathan P. Godbout et al. 2008; Kelley et al. 2013). Depressive symptoms are exacerbated in 
other inflammatory conditions, including ageing and obesity (Penninx et al. 2003; Milaneschi et 
al. 2009). Furthermore, human patients with hepatitis C or cancer that receive cytokine 
immunotherapy using interferon-alpha (IFNα) or IL-2 commonly experience symptoms of 
depression (Capuron et al. 2002, 2004). The finding that pharmacological blockade of cytokines 
improves symptoms independent of the clinical prognosis (Tyring et al. 2006) supports the link 
between inflammation and the neuropsychiatric cases of depression.  
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Overall, priming of microglia and their hyper-activation under inflammatory conditions 
contributes to and amplifies the neurodegenerative processes. However, a dichotomy exists 
where inflammatory stimuli may also induce tolerance in microglia, and attenuate subsequent 
inflammatory responses. This makes microglial priming an important research focus in the field 
of neurodegeneration. 
4.5 Cellular mechanisms downstream of hM3Dq 
A major consequence of Gq-signaling is an elevation of intracellular Ca
2+
, and our in vitro 
study validated that microglial hM3Dq triggers the expected Ca
2+
 elevation. The role of 
microglial Ca
2+
 signaling remains largely unknown and likely play diverse functions. With 
relevance to inflammation, it has been shown that a single stimulation with LPS leads to a long 
lasting elevation of calcium concentration in cultured microglia (Hoffmann et al. 2003) and a 
calcium chelator BAPTA prevents LPS-induced release of TNFα, IL-6, and nitric oxide 
(Hoffmann et al. 2003). Recent imaging studies using multi-photon microscopy revealed an 
interesting microglia calcium dynamics in vivo. Microglia display no spontaneous calcium 
transients under non-inflammatory conditions, but large calcium transients were induced by 
rupturing a single cell membrane within close proximity to microglia (Eichhoff, Brawek, and 
Garaschuk 2011).  
Interestingly, microglia response to laser burn injury showed 67% of microglia responding 
towards the lesion displayed calcium transients in LPS-primed brains, which was significantly 
higher than laser injury in non-LPS treated brains (Pozner et al. 2015). Data from Alzheimer’s 
models is in agreement with this, since microglia within close proximity to plaques shows 
elevated calcium transients (Brawek et al. 2014), and microglia isolated from postpartum brains 
of Alzheimer’s patients revealed microglia cells with elevated resting calcium levels and reduced 
response to ATP (Veerhuis, 2005), a result later confirmed in vivo (Brawek et al. 2014). An 
interesting question is the localization of hM3Dq signalling in microglia. hM3Dq appeared to co 
localize with Iba1+ microglia primarily in the processes (see Figure 3.2.2). This supports existing 
in vivo data showing calcium transients in microglia in response to LPS are primarily localized to 
the processes  Indeed, spontaneous calcium activity in microglia was increased 8-fold in 
response to injection of LPS (Figure 4.2), compared to baseline, and  >80% of transients were 
localized to the processes.  
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How exactly calcium signalling regulates microglia reactivity to inflammatory stimuli 
remains to be studied, but our finding suggests microglia-DREADD mice will be useful to 
dissect these mechanisms.  
4.6 Microglia-hM3Dq influence on peripheral inflammation 
 
Systemic administration of LPS is widely used to induce inflammatory response both in 
the periphery and in the brain. LPS is a large, hydrophilic molecule that does not cross the BBB, 
and the dose use used in this study (100 μg/kg) is unlikely to compromise the integrity of the 
BBB (Banks and Robinson 2010). A large body of studies have established that microglial 
activation is the result of peripheral cytokines signaling to the brain (Robert Dantzer et al. 2000). 
Accordingly, we measured plasma IL-6 levels, as an indicator for the magnitude of peripheral 
inflammation, and found that CNO treatment did not affect LPS-induced plasma IL-6 levels. 
Furthermore, we found that LPS-induced upregulation of mRNA for IL-6 and IL-1β in the spleen 
was not altered by hM3Dq activation in microglia. These data indirectly validate that peripheral 
monocytes that express CX3CR1 do not express hM3Dq (as predicted by the design of our 
mouse model) or if any hM3Dq activation in these peripheral monocytes does not substantially 
alter LPS-induced systemic inflammation. Importantly however, we found that levels TNFα 
mRNA in the spleen was attenuated in CNO-treated mice (despite the lack of change in IL-1β 
and IL-6 levels). One possible explanation for this isolated effect is that activation of microglial 
hM3Dq signalling in the brain may subsequently affects specific aspects of the peripheral 
inflammatory response via nerve outputs (Tracey 2009). This speculation is based on the notion 
that the brain regulates immune activities via both sympathetic and parasympathetic outflows. 
For example, stimulation of the vagal efferents strongly inhibit production of TNFα and protects 
animals from LPS-induced endotoxic shock, a mechanism known as the cholinergic anti-
inflammatory reflex (Borovikova et al. 2000). Chemokine induction by active microglia also 
transmits neuroinflammatory signals to the periphery and may represent a mechanism by which 
resident microglia signal to peripheral immune cells (Carson et al., 2006; Cazareth et al., 2014; 
Fenn et al., 2014b; Puntambekar et al., 2011; Wohleb et al., 2013). Future research should 
characterize peripheral inflammatory response in more detail as a potential downstream effects 
of microglial modulation by hM3Dq.   
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4.7 Microglia Morphology  
A major characteristic of microglia change of function is often a change in morphology. 
Microglia have been shown to acquire an ameboid morphology in response to inflammatory 
stimuli (Madore et al. 2013; Kettenmann et al. 2011). We found that cell body size, arborisation, 
and morphological index (Tremblay et al. 2012) were not altered by CNO in noninflammatory 
conditions. This supports our behavioural findings that microglia Gq-stimulation did not induce 
overt behavioural change, or mRNA expression of cytokines under healthy conditions. However, 
we did not find an effect of CNO on microglia morphology during inflammatory conditions. One 
possible explanation for this is that microglia morphological dynamics is not reactive to changes 
in microglia calcium signalling. Indeed, microglia Ca
2+
 activity decreases at later stages of 
inflammation, around 24 hr after LPS injection, but at this time point microglia morphology does 
not change, and their ameboid structure persists (Milior et al. 2016; O’Connor et al. 2009). This 
suggests morphology may not be sensitive to changes in calcium dynamics, which would 
exclude this microglia property from hM3Dq influence. However, we also did not find an effect 
of LPS on morphology. Previous studies have shown LPS-induced morphological changes to 
microglia (Choi et al. 2012; Hines et al. 2013; Norden et al. 2016; Wohleb et al. 2012), but the 
protocols used to analyze microglia morphology are inconsistent (Choi et al. 2012; Hines et al. 
2013; G. Luheshi et al. 1996; Madore et al. 2013; Milior et al. 2016). Research also shows that 
microglia shape exists along a continuum (Morrison et al. 2017; Town, Nikolic, and Tan 2005) 
In other words, the exact number of quantifiable microglia morphology changes is unknown. 
Thus, it is possible our chosen technique was not sensitive enough to the particular 
morphological change in our unique mouse model. Furthermore, the dosage of LPS and time 
point of analysis also varies across studies analyzing morphology and this is also likely to 
influence the result (Furube et al. 2018; Madore et al. 2013). Considering the  roles of 
endogenous microglia GPCRs in phagocytosis (Koizumi et al. 2007) future studies to assess the 
morphology of microglia following inflammatory stimuli/hM3Dq signalling are are warranted. 
4.8 Limitations 
Our transgenic mouse model are heterozygous for CX3CR1
CreER
 mice, in which knock-in 
of CreER results in knock out of endogenous Cx3CR1. Thus, our study used CX3CR1+/- mouse 
in all experiments and compared the effects of CNO versus vehicle. CX3CR1 receptor provides 
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bidirectional neuron-microglia signalling, and has previously been shown to alter microglia 
migration, hippocampal neurogenesis, pathology, and behaviour phenotypes (Bachstetter et al. 
2011; Hoshiko et al. 2012; Milior et al. 2016; Rosa C. Paolicelli et al. 2011). Most of these 
studies detected abnormality in homozygous KO CX3CR1 
-/-
 (Zanier et al. 2016; Zhan et al. 
2014), and therefore, it is generally considered that heterozygous CX3CR1
-/+
 maintain normal 
phenotype. Nevertheless, we cannot exclude the possibility of the influence of CX3CR1 
heterozygosity on their response to LPS, CNO and interaction of both. Importantly, however, our 
experiments were designed to compare DREADD activation among CX3CR1+/- hM3Dq 
expressing mice. Thus, the effects of CX3CR1 deficiency, if any, should occur equally in CNO 
and vehicle treated mice. It must be noted that experiments were only completed in young male 
mice. Aged mice display primed microglia that display elevated inflammatory responses 
(Niraula, Sheridan, and Godbout 2017), thus, the hM3Dq-mediated modulation of microglia 
could be different in older mice. Second, there are notable differences between microglia and 
neuroimmune signalling in the male and female brain throughout the lifespan (Lenz and 
McCarthy 2015). For instance, qPCR validates that male and female microglia follow distinct 
gene expression patterns after acute LPS challenge (Hanamsagar et al. 2015). Future studies 
should attempt to replicate this experiment using female mice in order to determine if hM3Dq 
modulation is different compared to in the male brain.  
Microglia are not the only cell types known to synthesize cytokines in the brain. Astrocytes 
also respond to LPS-induced inflammation by upregulating cytokines, albeit at a later time point 
compared to microglia (Norden et al. 2016). It is unknown in the present study what the exact 
contribution of astrocytes are for our measurements 2 hour after the injection of LPS. Hence the 
partial attenuation of cytokine synthesis we observed might be related to the fact that our 
approach only changed Ca
2+
 signalling in microglia. To this point, it has been suggested that 
endogenous GPCRs expressed by microglia can modulate astrocyte neuroinflammatory 
responses, and these are calcium dependant (Quintas et al. 2014). For instance, in LPS treated 
co-cultures of astrocytes and microglia, UTP is rapidly converted into UDP, which activates 
P2Y6 receptors, inducing the release of NO by microglia that causes astrocyte apoptosis, thus 
controlling their rate of proliferation and preventing an excessive astrogliosis (Quintas et al. 
2014). Furthermore, modulation of astrocytes has been shown to alter neuronal activity and 
behaviour (Halassa and Haydon 2010).  In another study, microglia signals in the form of IL-1α, 
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TNFα, and C1q induced astrocytes towards a neurotoxic phenotype which contributed to 
pathology (Liddelow et al. 2017). In a final example, in vitro studies suggest astrocytes, and also 
endothelial cells, modulate microglia activation states. Astrocytes and endothelial cells were 
subject to oxygen glucose deprivation, and their conditioned media were transferred to microglia. 
Microglia exposure to conditioned media led to elevation of classic activation markers compared 
to baseline, including proinflammatory cytokines and surface markers like CD11b, CD45, CD68, 
MHC class II (Xing et al. 2018). These studies outline the bidirectional communication of 
microglia and astrocytes and acknowledge the importance of considering these glia cells as well. 
Future studies should investigate the specific contribution of astrocytes in sickness, and whether 
they are potentially modulated by downstream microglia signalling. In line with this, we cannot 
say how hM3Dq is actually modulating microglia activity.  
Recent studies indicated that CNO itself is a relatively low affinity agonist for DREADDs and 
that clozapine to which CNO converts to in vivo acts on DREADDs (Gomez et al. 2017; 
MacLaren et al. 2016). Also it has been proposed that CNO poorly crosses the BBB and in vivo 
efficacy of CNO requires its conversion to clozapine, which crosses the BBB. In previous in 
vitro experiments performed by our lab in cultured microglia, CNO had very fast effects 
consistent with direct activation of hM3Dq (as the culture setting lacks CNO metabolizing 
enzyme). On the other hand, in wild-type mice that do not express hM3Dq, CNO alone did not 
affect cytokine synthesis in response to LPS. Furthermore, our lab has completed behavioural 
investigation in wildtype controls that lack DREADD expression and have found no effect of 
CNO. While a few earlier studies reported non-specific effects of CNO, which came results from 
the actions of clozapine, on some behavior, those studies used higher doses (2.0 – 20.0 mg/kg) in 
comparison to the dose we used (1.0 mg/kg) (MacLaren et al. 2016; Manvich et al. 2018). 
Another drug used in this study, tamoxifen, has been suggested to have side effects. Tamoxifen 
is a selective estrogen receptor modulator (SERM) which binds to ERs and elicits either agonist 
or antagonist activity depending on the tissue it is acting in (Patel et al. 2017). Since it is a potent 
agonist in breast tissue, it has become a popular treatment for breast cancer. However, due to 
these effects on the endocrine system, it has been implicated in reproductive dysfunction (Patel 
et al. 2017), and likely effects bone mineral density (Vehmanen et al. 2006). In these studies, 
mice treated with tamoxifen experienced acute weight loss of 3-6 grams. However, mice quickly 
regained weight, and no additional side effects of tamoxifen were detected. Furthermore, all mice 
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were injected with tamoxifen, suggesting any differences between vehicle and CNO treated 
microglia-hM3Dq mice are not due to inadvertent effects of tamoxifen.  
4.9 Conclusion  
Whether the activation of Ca
2+
 by hM3Dq only in microglia can somehow desensitise 
further LPS-induced Ca
2+
 signalling is an intriguing question that remains to be answered. 
Regardless, we provide a proof of principle that specific regulation of GPCR signalling in 
microglia is a powerful approach to regulate cytokine synthesis and sickness behavior. Our data 
suggest that attenuation of cytokine synthesis by microglia can attenuate certain behavioral 
aspects related to sickness. This new approach that avoids the use of virus to express hM3Dq in 
microglia can open new avenues to understand how neurons communicate with microglia and 
vice-versa in a number of other experimental settings, including during development and in 
mouse models of neurodegenerative diseases. 
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